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ABSTRACT 
Host-pathogen interactions of secreted and surface Staphylococcus aureus factors 
Publication No. ____________ 
Vanessa Vazquez 
Supervisory Professor:  Magnus Höök, Ph.D. 
 
Staphylococcus aureus is an opportunistic bacterial pathogen that can infect 
humans and other species.  It utilizes an arsenal of virulence factors to cause disease, 
including secreted and cell wall anchored factors.  Secreted toxins attack host cells, and 
pore-forming toxins destroy target cells by causing cell lysis. S. aureus uses cell-surface 
adhesins to attach to host molecules thereby facilitating host colonization.  The Microbial 
Surface Components Recognizing Adhesive Matrix Molecules (MSCRAMMs) are a family 
of cell-wall anchored proteins that target molecules like fibronectin and fibrinogen.  The 
Serine-aspartate repeat (Sdr) proteins are a subset of staphylococcal MSCRAMMs that 
share similar domain organization.  Interestingly, the amino-terminus, is composed of three 
immunoglobulin-folded subdomains (N1, N2, and N3) that contain ligand-binding activity.  
Clumping factors A and B (ClfA and ClfB) and SdrG are Sdr proteins that bind to fibrinogen 
(Fg), a large, plasma glycoprotein that is activated during the clotting cascade to form fibrin.  
In addition to recognizing fibrinogen, ClfA and ClfB can bind to other host ligands.   
Analysis of S. aureus strains that cause osteomyelitis led to the discovery of the 
bone-sialoprotein-binding protein (Bbp), an Sdr protein.  Because several MSCRAMMs 
target more than one molecule, I hypothesized that Bbp may recognize other host proteins.  
A ligand screen revealed that the recombinant construct BbpN2N3 specifically recognizes 
human Fg.  Surface plasmon resonance was used to determine the affinity of BbpN2N3 for 
Fg, and a dissociation constant of 540 nM was determined.  Binding experiments performed 
with recombinant Fg chains were used to map the binding of BbpN2N3 to the Fg Aα chain. 
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Additionally, Bbp expressed on the surface of Lactococcus lactis and S. aureus Newman 
bald mediated attachment of these bacteria to Fg Aα.  To further characterize the 
interaction between the two proteins, isothermal titration calorimetry and inhibition assays 
were conducted with synthetic Fg Aα peptides.  To determine the physiological implications 
of Bbp binding to Fg, the effect of Bbp on fibrinogen clotting was studied.  Results show that 
Bbp binding to Fg inhibits the formation of fibrin.  The consequences of this interaction are 
currently under investigation.   
Together, these data demonstrate that human Fg is a novel ligand for Bbp.  This 
study indicates that the MSCRAMM Bbp may aid in staphylococcal attachment by targeting 
both an extracellular matrix and a blood plasma protein.  The implications of these novel 
findings are discussed.
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CHAPTER I 
Introduction 
 
Staphylococcus aureus is an opportunistic pathogen that causes a multitude of 
diseases in humans and other species.  It was discovered in the 1880s by Sir Alexander 
Ogston as a cause of abscess infections, and its name originates from the Greek “staphyle” 
and “kokkos” for “bunch of grapes” and the Latin “aureus” for “golden” because the 
organism exists in clusters, and its colonies are yellow in color (1).   S. aureus is a gram-
positive organism that contains a cell wall composed of peptidoglycan and lipoteichoic acid. 
The bacterium is catalase-positive, ferments mannitol, produces coagulase, and is not 
motile.  Although S. aureus is aerobic and grows best at 30-37°C, it tolerates growth at low 
oxygen, under high osmotic pressure and at a wide temperature range (82) (12).  
  
Types of S. aureus infections 
 Approximately 30-50% of healthy humans are colonized on the skin or nares with S. 
aureus, and 20% of the population is considered to be persistent carriers.  Persistent 
carriage of the bacterium increases the risk of developing infections.  Additionally, 
individuals with acquired immune deficiency syndrome, diabetes, or post-surgery are at 
increased risk of developing infections. Nosocomial infections are obtained by patients who 
are currently undergoing treatment for another complication, especially by post-operative 
patients (82). 
 S. aureus has the ability to cause different diseases.  Infections range from mild skin 
diseases like boils and pimples to more invasive illnesses.  Uncomplicated skin and soft 
tissue infections (SSTIs) include cellulitis, impetigo, and furuncles (82).   Fortunately, these 
infections can be successfully treated by surgical drainage and antibiotics (92).  
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Contrastingly, patients with complicated SSTIs may present with tissue necrosis and 
sepsis.  They require admission into the hospital because they are at high risk of mortality 
or limb-loss (92).   Prolonged uncomplicated SSTIs can also lead to development of 
osteomyelitis or necrotizing fasciitis (31).  Furthermore, individuals may suffer from 
recurrent SSTIs, which may be remedied by decolonization (31). 
Bacteremia is the presence of bacteria in the blood.  The source of the systemic 
bacteria may be a localized focus of infection (72).  Consequences of bacteremia arise as 
the bacteria leave the bloodstream and colonize other tissues like the kidney or 
endocardium.  Bacteremia may also lead to life-threatening sepsis.  S. aureus sepsis 
involves systemic inflammation, and severe sepsis includes acute organ failure.  Sepsis is 
usually associated with bacteremia, and can be secondary to bacterial infection of the 
urinary tract, bone, kidney, or lungs (49) (53).  Patients can be admitted into the intensive 
care unit for treatment, which can last for a few weeks.  
S. aureus is the leading cause of osteomyelitis, characterized as an acute or a 
chronic bone infection.  Pediatric patients often suffer from the hematogeneous form of 
osteomyelitis, which is accompanied by a fever.  Hematogeneous osteomyelitis usually 
develops in long bones, like the femur and tibia, after colonization from the blood (115) 
(117).  In adults, osteomyelitis is usually developed due to spread of a soft tissue infection 
or by introduction of S. aureus bacteria after trauma to the bone (115).  
 The second leading cause of food-borne illness is S. aureus.   Gastroenteritis is 
characterized by nausea, abdominal cramps, diarrhea, and vomiting (7).  Disease develops 
approximately 30 minutes to 8 hours after ingestion of contaminated food (7) (73).  In 
addition to its fast onset, non-life-threatening S. aureus gastroenteritis can subside within 
24 hours of illness (73).  Although rare, gastroenteritis can lead to death, and elderly 
individuals have a higher incidence of mortality (7).  
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 S. aureus is a causative agent of toxic shock syndrome (TSS), a severe disease 
characterized by high fever, capillary leakage, hypotension, and often involves rash, 
diarrhea and vomiting, and disseminated intravascular coagulation. S. aureus is considered 
the sole etiology of TSS associated with tampon use in women, where there is also a 
presence of ulcerative vaginitis (27).  TSS is a major problem in pediatric burns, and it is the 
most frequent cause of unexpected deaths in these patients (141).  Currently, pediatric burn 
cases have surpassed the amount of menstruation-related TSS (141). 
 S. aureus infections can cause pneumonia, an infection of the lungs.  Necrotizing 
pneumonia, which is characterized by inflammation, vascular leakage, and tissue 
destruction in the lungs is severe (23).  S. aureus is the most frequently isolated pathogen 
from patients suffering from ventilator-associated pneumonia due to colonization of the 
lower airways after mechanical ventilation (4). 
 Infective endocarditis is a complication of S. aureus disease with a mortality rate of 
20-30%.  Symptoms of disease are fever and fatigue.  It involves infection of the 
endovasculature and, commonly, implanted materials like prosthetic heart valves (136).  
Pediatric endocarditis is associated with children suffering from congenital heart disease 
(2).  A recent report found that S. aureus was the etiologic agent of infective endocarditis in 
40% of the study group (2).  
 
S. aureus antibiotic resistance and therapy  
 S. aureus has acquired the ability to resist the action of antibiotics (29). Methicillin-
resistant S. aureus (MRSA) has become predominant in hospital settings, accounting for 
the majority of nosocomial infections worldwide (82).  These strains are referred to as 
hospital associated-MRSA (HA-MRSA).  Patients with HA-MRSA have established risk 
factors such as prolonged hospitalization, prolonged antimicrobial therapy, surgical 
procedures, dialysis, indwelling vascular devices, and proximity to patients in the hospital 
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who are infected or colonized with MRSA (82).  However, MRSA cases have been recently 
reported in healthy individuals with no established risk factors.  Because these infections 
are apparently acquired in the community and are not related to the hospital environment, 
they are referred to as community-associated MRSA (CA-MRSA) (59) (51).  CA-MRSA 
cases are now being reported all over the world, and their numbers are climbing.  Infections 
due to CA-MRSA seem to primarily affect children and young adults with no predisposing 
factors.  Contrary to HA-MRSA, CA-MRSA strains are susceptible to most antimicrobials 
except for β-lactams (32), but due to the rapid onset of complications, treatment is often 
ineffective. 
 Antibiotic resistance may arise by three mechanisms.  The first is acquired 
resistance via a horizontal transfer, from other bacteria, of genes that encode for a 
resistance-conferring molecule, commonly, the mecA gene product, which is a penicillin-
binding protein.  Secondly, chromosomal mutations can give rise to resistance.  The third 
mechanism is antibiotic selection (18). 
Antibiotics may select for resistant organisms by killing the susceptible population 
and leaving only the resistant bacteria, which then multiply causing an antibiotic-resistant 
infection (122).  Studies suggest that some antibiotics may be better at selecting for 
resistance than others due to the ability of a particular compound to possess higher 
diffusion capabilities, as is the case of fluoroquinolones (122).  Additionally secretion of the 
antibiotic into the individual’s sweat could eradicate susceptible bacteria on the skin, which 
has been shown for ciprofloxacin (61).  It has been postulated that vancomycin resistance 
may be associated with selection on strains colonizing the intestines.  It is generally 
believed that vancomycin resistance frequency decreases as use of vancomycin decreases 
(122). 
The standard therapies for S. aureus infections are antibiotics.  Nafcillin and 
oxacillin are the common therapeutics for susceptible S. aureus strains.  Due to increased 
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development of resistance, rifampin, is not used alone but in combination with other 
antibiotics, like nafcillin or vancomycin (37).  SSTIs and CA-MRSA are treated with 
clindamycin, trimethoprim-sulfamethoxazole, or doxycycline (52).  Vancomycin is the 
preferred treatment for other MRSA infections and for endocarditis (93).  However, 
pneumonia and bone infections are treated with linezolid and clindamycin, respectively, due 
to their abilities to penetrate tissues (52).  New studies suggest the use of daptomycin 
instead of standard therapy for endocarditis (64), possibly due to its lowered toxicity (41).  
 
S. aureus pathogenesis 
 S aureus causes disease by attaching to host tissues, which it will subsequently 
colonize.  Following these events, S. aureus establishes infection by killing host cells, 
interfering with host pathways, evading the immune response, and spreading to other sites 
(82).   Furthermore, bacteria can form biofilms, which are difficult to treat with antibiotics.  In 
order to accomplish infection, S. aureus has an arsenal of virulence factors. 
 
Adhesins 
 Adhesins are surface proteins used by the bacteria to attach to host molecules (39).  
After protein expression, they are secreted.  Following transport, adhesins are anchored to 
the cell wall peptidoglycan by a sortase enzyme via a motif at the carboxy terminus (94).  
The LPXTG motif is used by sortase A to covalently link adhesins to the peptidoglycan via a 
transpeptidase reaction (94).  Specifically, the sortase cleaves the bond between the 
threonine and the glycine, and the protein is anchored to the wall at the pentaglycine 
crossbridges.  Sortase B uses the NPQTN motif (85).  Using sequence analysis to identify 
staphylococcal proteins containing the LPXTG or NPQTN motif, 22 cell-wall anchored 
proteins have been identified, and a function has been attributed to half of these putative 
adhesins.   
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Microbial surface components recognizing adhesive matrix molecules 
(MSCRAMMs) are cell-wall anchored proteins that adhere to the host extracellular matrix or 
serum proteins (99).  All of the characterized adhesins are MSCRAMMs.  They target 
collagen, fibronectin, elastin, fibrinogen, and other molecules.  They are redundant in their 
specificity, as S. aureus expresses at least two MSCRAMMs that recognize fibronectin, two 
that bind to heme, and at least four proteins that target fibrinogen.  While the reason for this 
redundancy is unknown, our laboratory and others are working to elucidate the reason for 
this phenomenon and speculate the following reasons.  First, some of the host proteins, like 
fibrinogen and fibronectin, are larger than 300,000 daltons and are composed of different 
polypeptide chains or different motifs that are involved in many reactions with other host 
cells, plasma proteins, or extracellular matrix.  Secondly, the MSCRAMMs for which a 
ligand-binding site has been characterized appear to target many different sites within the 
same protein.  This is the case for fibrinogen-binding MSCRAMMs (43) (22) (131).   
MSCRAMMs share secondary structure similarities, although their linear sequence 
may contain little identity.  The domain organization of many MSCRAMMs can be described 
from amino to carboxy terminus (Figure 1-1).  Approximately the first 30 residues encode a 
signal sequence that targets the protein for transport to the cell surface (94).  Next, the A 
domain has been characterized as the ligand-binding domain. C-terminal to the A domain, 
MSCRAMMs possess one or two repeat regions. Some of these repeated domains are 
believed to act as stalks that help the adhesin extend away from the cell surface.  At the 
carboxy terminus, there is a wall-spanning region, followed by a membrane-spanning 
region.  Between the latter two domains is the LPXTG anchoring motif (39).  
 
Protein A 
Protein A may be the most characterized surface protein of S. aureus.  Protein A 
binds to the plasma protein, von Willebrand factor (vWF) (57).  This interaction can mediate  
 8 
 
 
 
 
Figure 1-1.  Domain organization of MSCRAMMs. Fibronectin binding protein A (FnbpA) 
(A), Collagen adhesin (Cna) (B), Clumping factor A (ClfA) (C), Protein A (Spa) (D).  S: 
signal sequence; A: amino terminal A domain; B: B repeats; R: Serine-Aspartate repeats; 
W: wall spanning region; M: membrane spanning region; Wr: octapeptide repeat; Wc: non-
repeated domain.  Reprinted from Trends in Microbiology, 6 (12), TJ Foster and M Hook, 
Surface protein adhesins of Staphylococcus aureus, 484-488, 1998, with permission from 
Elsevier Limited (39). 
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attachment of S. aureus bacteria to vWF coated materials under shear flow forces (57).  
Protein A has also been characterized as a tumor necrosis factor receptor protein 1 
(TNFR1)-binding protein (48).  This interaction triggers airway inflammation in a murine 
pneumonia model (47).  The most studied function of Protein A is its binding to the Fc 
region of immunoglobulin heavy chain (38).   The structure of the binding domain in 
complex with the Fc fragment has been solved (24).  In humans, Protein A can bind to IgM, 
IgA, and IgE but not as readily as it binds to IgG. Typically, antibodies recognize bacterial 
determinants with the variable region and bind to their cell-surface receptors via the Fc 
region.  Because antibodies bind to Protein A via their Fc region, they are not available to 
ligate Fc receptors to stimulate immune clearance. Via its interaction with IgG, Protein A 
mediates an inhibition of phagocytosis.  Furthermore, Protein A mutants are phagocytosed 
more readily that wild-type (50). 
 
Fnbps 
S. aureus encodes two fibronectin binding proteins, FnbpA and FnbpB that also 
share similar domain organization (see Figure 1-1).  They have been shown to confer 
binding of bacteria to fibronectin type I modules. S. aureus has long been considered to be 
an extracellular pathogen; however, FnbpA and FnbpB can mediate cell invasion by a 
mechanism that involves forming a fibronectin bridge with host cell α5β1 integrins (40).  
Additionally, the Fnbps are capable of binding to fibrinogen, and FnbpA also binds to 
elastin.  Interestingly, FnbpA binds to fibrinogen and elastin via the same site (66). 
 
Cna 
Collagen is targeted by the collagen binding adhesin, Cna.  This protein has been 
shown to increase the virulence of S. aureus in a murine septic arthritis model, and it may 
also play a role in endocarditis (26) (60). Moreover, Cna was shown to be important for 
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hematogeneous spread in a murine osteomyelitis study (28).  The structures of both the 
apo-form and Cna in complex with a synthetic collagen peptide have been solved, and the 
collagen-hug model has been proposed based on experimental data (142).   
Cna binds to collagen via the N1 and N2 domains, which are connected by a linker 
region.  The pocket between the N1 and N2 domains accommodates the binding of the 
triplex helix.  Upon ligand binding, Cna and Ace wrap around or “hug” the collagen peptide, 
resulting in a tunnel formed by the linker and the N1 and N2 domains where the peptide 
can be held (Figure 1-2) (142).  
 
Isds 
Iron-responsive surface determinants (Isd) proteins are another family of cell-wall 
anchored proteins.  In order to survive in host systems, S. aureus must acquire iron, which 
is usually in complex with other molecules in the form of porphyrins or transferrin.  IsdA and 
IsdC (86) can bind to heme; whereas IsdB recognizes heme and hemoglobin (83).  A recent 
report determined the ability of IsdB to bind to the platelet integrin αIIbβ3 which leads to 
platelet adhesion and aggregation (21).  IsdH can bind to haptoglobin in order to sequester 
the iron.  Interestingly, the Isd proteins are found in an operon that also encodes for the 
sortase B and transporter proteins IsdDEF (86).   
 
Clfs 
The clumping factors A and B (ClfA, ClfB) also target many ligands.  Their basic 
domain organization is very similar: an amino-terminal ligand-binding domain and a carboxy 
terminal serine-aspartate repeat (SD) region.  Thus, ClfA and ClfB are part of the Sdr 
subfamily of MSCRAMMs (Figure 1-3).  The ligand-binding subdomain constructs of both 
proteins have been crystallized and the structure of ClfA in complex with a fibrinogen  
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Figure 1-2.  Cartoon representation of the collagen hug model. (A) Collagen interacts with 
the N2 domain. (B)  The linker between N1 and N2 wraps the N1 around collagen (C) 
Collagen is latched into position and N1 and N2 residues interact.  Reprinted by 
permission from MacMillan Publishers Ltd:  EMBO Journal, Y Zong, Y Xu, X Liang, DR 
Keene, A Höök, S Gurusiddappa, M Höök, SV Narayana, A ‘Collagen Hug’ model for 
Staphylococcus aureus Cna binding to collagen, 24(24), 4224-4236, 2005 (142).  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Figure 1-3.  Domain organization of the Sdr proteins. (A) ClfA: Clumping factor A; (B) 
Clumping factor B; (C) SdrC: SD repeat protein C; (D) SdrD: SD repeat protein D; (E) SdrE: 
SD repeat protein E; (F) Bbp:  Bone sialoprotein-binding protein.  S:  signal sequence; A: 
amino terminal A domain; B: B-repeats; R: SD repeat region; M: membrane spanning region.  
Green: proline-rich region; Red: EF-hands; Blue:  TYTFTDYVD.  Adapted from Trends in 
Microbiology, 6 (12), TJ Foster and M Hook, Surface protein adhesins of Staphylococcus 
aureus, 484-488, 1998, with permission from Elsevier Limited (39). 
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peptide has been solved (43) (25).  ClfA and ClfB recognize different Fg chains: γ and α, 
respectively (43) (131) .   
ClfA is considered to be the principal protein contributing to clumping by binding to 
fibrin clots.  Moreover, it has been shown to play a role in a rat endocarditis model of 
infection (30), and enriched pooled immunoglobulins against ClfA had therapeutic effects 
against a catheter-induced aortic valve infective endocarditis rabbit model.  (130).  ClfA can 
interfere with Factor XIII mediated fibrin formation (79).  In addition, ClfA binds to 
complement regulator factor I, which increases cleavage of the complement protein C3b 
(54).  ClfB also binds to cytokeratin 10 and plays a role in binding to nasal epithelial cells 
(134) (132).   
 
SdrG 
SdrG is a Fg-binding MSCRAMM of S. epidermidis.   SdrG is discussed here 
because its structure and binding mechanism may closely mimic that of S. aureus 
MSCRAMMs discussed in detail throughout these studies.  It targets the thrombin cleavage 
site of the Bβ chain, and inhibits the release of fibrinopeptides B, which, in turn, inhibits the 
formation of fibrin (22). Its ligand-binding trench lies between the N2 and N3 domains. 
The structures of apo-SdrGN2N3 and of the complex formed by SdrGN2N3 with a 
peptide corresponding to the Bβ chain residues 6-20 were solved to determine the binding 
mechanism.  The co-crystal structure shows that the peptide binds to a trench between the 
two immunoglobulin-like N2 and N3 domains (Figure 1-4) (102).  In the dock, lock, and latch 
(DLL) mechanism, the Fg peptide docks into the ligand-binding trench formed between the 
N2 and N3 domains of SdrGN2N3.  Next, the peptide is locked by a redirection of residues in 
the C-terminus of N3, which ultimately form a latch that holds the peptide in the ligand-
binding trench by forming a β-strand by complementation (102) (10).   
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Figure 1-4.  See next page for legend. 
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Figure 1-4.  Previous page. Structural representation of the dock, lock, and latch model  
(A)  Domain organization of SdrG.  (B)  Structure of SdrGN2N3.  Yellow: N2, green: N3, red 
wavy line: lock and latch residues.  1)  Open, unbound protein; 2)  Ligand (purple) docks 
into the ligand binding trench; 3)  The lock residues are redirected by ligand; 4)  The latch 
forms a β-strand with the N2 domain holding the ligand in place.  (C)  Models for 1) 
permanently open SdrG(S483C,P595C)  and 2) permanently closed SdrG(E381C, 
P595C). Inset:  zoom view of the disulfide bond that covalently closes N2N3.  Printed with 
permission from Journal of Biological Chemistry for nonprofit/noncommercial use :  MG 
Bowden, AP Heuck, K Ponnuraj, E Kolosova, D Choe, S Gurusiddappa, SVL Narayana 
AE Johnson, and M Hook, Evidence for the “Dock, Lock, and Latch” Ligand Binding 
Mechanism of the Staphylococcal Microbial Surface Component Recognizing Adhesive 
Matrix Molecules (MSCRAMM) SdrG, 283, 638-647, 2008 (10). 
 
 
 
 
 
Figure 1-5. Below.  Cartoon representation of the binding between SdrG and fibrinogen.  
(A)  The N2 and N3 regions are in open conformation without ligand and the B-repeats 
are extended.  (B)  The Fg peptide (red) is bound and the N2N3 domains are closed; the 
B repeats are compact due to the redirection of the latching residues.  Printed with 
permission from Journal of Biological Chemistry for nonprofit/noncommercial use :  MG 
Bowden, AP Heuck, K Ponnuraj, E Kolosova, D Choe, S Gurusiddappa, SVL Narayana 
AE Johnson, and M Hook, Evidence for the “Dock, Lock, and Latch” Ligand Binding 
Mechanism of the Staphylococcal Microbial Surface Component Recognizing Adhesive 
Matrix Molecules (MSCRAMM) SdrG, 283, 638-647, 2008 (10). 
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To biochemically support the findings, further experiments were performed using 
SdrGN2N3 mutants (10).  The apo form of SdrGN2N3 has an available ligand trench, and a 
flexible N3 extension, or latch, this form is referred to as “open.”  However, in the protein-
peptide complex the N3 extending residues have been redirected to cover the ligand 
pocket; this form of the protein is referred to as “closed.”  Therefore, mutations were 
introduced to force the protein to exist in either the open or closed conformations (Figure 1-
5).  Binding and Forster resonance energy transfer experiments confirmed that the peptide 
can only bind to an open conformation that closes after ligand binding (Figure 1-5) (10).  
Because the Sdr proteins are similar in domain organization and folding, the dock, lock, and 
latch mechanism of binding has been proposed for the Sdr family of MSCRAMMs 
 
Bbp 
Studies with S. aureus strains that cause osteomyelitis led to the discovery that the 
bacteria bind to bone-sialoprotein (BSP) (110).  Biochemical studies were used to attribute 
BSP binding to the determinant, bone-sialoprotein-binding protein (Bbp) (138).  The binding 
residues were mapped to the amino-terminus of BSP.  Bbp is an MSCRAMM in the Sdr 
sub-family; therefore, it shares similarities with the clumping factors and SdrG.  Bbp has the 
conserved TYTFTDYVD motif in the A domain and three B-repeats.  Antibody titers to Bbp 
are high in diabetic osteomyelitis patients.  Clinically, anti-Bbp sera may be used to 
differentiate cases of osteomyelitis from soft tissue infections (101).   
 
Fg - a common MSCRAMM target 
Fibrinogen (Fg) is a 340 kDa dimeric glycoprotein composed of two sets of three 
polypeptides, Aα, Bβ, and γ that are covalently linked by disulfide bonds (Figure 1-6).  The 
central region of the dimer contains the amino-termini of the chains.  Following the central 
domain is a coiled-coil region.  The ends of the dimer are globular, and the Aα chain forms  
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Figure 1-6. Structure of fibrinogen. (A) Individual Fg chains, Aα, (blue) Bβ (green) and 
γ (red),  FpA and FpB: fibrinopeptides A and B; black bars: disulfide bonds; triple 
arrows: plasmin cleavage sites for D and E fragments; single arrows: cleavage sites 
for removal of αC and BβN regions. (B) Crystal structure of fibrinogen.  (C) Fibrinogen 
structure and other regions not crystallized: the αC-domains; αC-connectors; the 
amino-terminus of Bβ (BβN) displayed with random conformations; the A, B, and P 
domains of the D region; the holes and nodules are asterisked.    Reprinted from 
Journal of Thrombosis and Haemostasis 7, 355-359, L Medved and JW Weisel, 
Recommendations for nomenclature on fibrinogen and fibrin, 2009 with permission 
from John Wiley and Sons (88). 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a hairpin that directs its carboxy-terminus away from the ends of the dimer towards the 
central region (Figure 1-6).  Crystallographic studies have elucidated the structure of Fg; 
however the carboxy-terminus of the Aα chain (αC) has not been crystallized with the rest 
of the molecule (67) (139).  Instead, part of the αC structure has been solved with nuclear 
magnetic resonance using smaller constructs (17) (128).  
Hepatocytes synthesize 1.7-5 grams of Fg per day.  Approximately 75% of the Fg is 
found in the plasma, while the rest is in the interstitium and lymph (123). Evidence of non-
hepatocyte synthesis also exists (76).  In addition, platelets may endocytose Fg, as it has 
been found in the α granules (56) (55).  
The major role of Fg is to form fibrin clots.  During the clotting cascade, prothrombin 
is activated, and thrombin cleaves fibrinopeptide A from the amino-terminus of the Aα 
chain, which exposes the ‘a’ knobs.  The result is a fibrin monomer that binds to other fibrin 
monomers to form fibrin protofibrils (91).  Next, thrombin cleaves fibrinopeptide B from the 
amino-terminus of the Bβ chain, exposing the ‘b’ knobs (140).  The protofibrils associate 
with each other to form fibrin fibers.  Factor XIIIa is a transglutaminase that catalyzes the 
formation of covalent bonds between the α and γ chains, this crosslinks the fibrin fibrils 
(116), forming an insoluble meshwork.  Plasmin cleavage can degrade fibrin into one E and 
two D fragments (88).   
Fg possesses a multitude of biological functions involving interactions with other 
proteins and cells in addition to its coagulation function.  The β chain mediates the 
interaction between fibrin and heparin (97).  Moreover, it can bind to endothelial cells via 
vascular endothelial-cadherin (5).  Fibrinogen contains three arginine-glycine-aspartate 
(RGD) sites:  two in the Aα chain and one in the γ chain, that interact with α5β1, αvβ3, and 
αIIbβ3 integrins on endothelial cells, fibroblasts, and platelets (119) (42) (3).  In addition, 
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fibrinogen can bind to leukocytes via αMβ2 (36).   The Aα chain can also bind to fibronectin 
(84). 
 
MSCRAMM-mediated platelet activation  
MSCRAMMs bind to platelets leading to activation and aggregation.  In the 
presence of fibrinogen, platelet binding is enhanced (34) (Figure 1-7).  The Fnbps use 
fibrinogen and fibronectin bridges with the platelet integrin αIIbβ3 to activate platelets.   
Furthermore, the activation may occur via bridging FcγRIIa on platelets with antibodies 
specific for Fnbps (35).  Also, Protein A, ClfA, ClfB, and SdrE all bind to platelets causing 
their aggregation (96).  Although no ligand has been reported for SdrE, its ability to bind to 
platelets was dependent upon the presence of an unknown plasma protein.  Protein A can 
activate platelets via a direct interaction or through an immunoglobulin bridge to surface Fc 
receptors (96). 
Surface anchored proteins contribute to the pathogenesis and survival of S. aureus 
in host tissues and blood.  By binding to extracellular proteins, MSCRAMMs may mediate a 
stealth form and help the bacterium hide from host defense mechanisms, which they 
accomplish by coating the bacterial surface with host proteins or by invasion into host cells. 
 
Toxins 
 Toxins are secreted bacterial proteins whose activities lead to host cell death. 
Targets have been identified for many staphylococcal toxins, and some are associated with 
a specific disease manifestation. 
 The α-, β-, γ-, and δ-hemolysins, leukocidin, and Panton-Valentine leukocidin (PVL) 
may all be encoded by a particular S. aureus strain.  The α- and γ-hemolysins, leukocidin 
and PVL are part of the pore-forming toxin family.  The α-toxin, or α-hemolysin (α-HL), has  
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been widely studied.  It inserts into the host cell membrane as a heptamer, and forms β-
barrel pores on the surface.  Multiple pores on the cell surface can lead to cell death.  
Virulence conferred by α-HL has been implicated in many models of staphylococcal 
disease including mastitis, pneumonia, and subcutaneous lesions (11) (98) (16).  In addition 
to red-blood cells, the toxin also targets immune and epithelial cells.  Additionally, β-toxin is 
a sphingomyelinase that has been implicated in a mammary gland infection model (11).  
The δ-hemolysin is a small cytolysin and phenol-soluble modulin that can insert into the 
membrane of host cells (33).  PVL, γ-hemolysin and leukocidin are bi-component toxins that 
require both subunits to bind to their target cells.  The S. aureus hlg locus encodes three 
proteins:  HlgA, HlgB, and HlgC.  The HlgA-HlgB combination forms the hemolysin; 
whereas, the HlgB-HlgC combination forms leukocidin.  The γ-hemolysin has been 
implicated in a rabbit endophthalmitis model of infection (121).  PVL is specific for 
polymorphonuclear cells, monocytes, and macrophages, and its two components are LukS-
PV and LukF-PV.  CA-MRSA strains including the predominant clone, USA300, produce 
this toxin (125).  These cytotoxins can target many cell types and have been implicated in 
various S. aureus diseases. 
 The staphylococcal enterotoxins (SE) and toxic shock syndrome toxin (TSST-1) are 
pyrogenic toxin superantigens (PTSAgs) and have been directly implicated in virulence.  
They bind to human major histocompatibility complex class II (MHCII) and T cell receptors 
(TCR) forming a crosslink between the two proteins.  This interaction leads to T cell 
proliferation and release of cytokines causing an overwhelming inflammatory response in 
the host (90) (62).  PTSAgs induce expansion of T cells specific for the TCRβ-chain 
variable region (109).  TSST-1 and some SEs also cause vomiting.  Staphylococcal food 
poisoning is attributed to the SEs, and it has been hypothesized that this is due to 
inflammation in the gastrointestinal tract caused by localized SE emetic reflex (63).  TSST-1 
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is considered as the cause of all menstruation-related TSS.  TSST-1 permeates and 
crosses the vaginal mucosa, explaining why patients do not appear bacteremic when 
suffering from menstruation-related TSS.  Crystallographic data has been used to 
determine the interacting residues between PTSAgs and their targets.  Depending on their 
exact location within the molecule, mutations in the TCR or MHCII binding residues may 
diminish or enhance activity or the PTSAgs (77). 
 
Other virulence factors used for immune evasion 
Phagocytosis is a major mechanism of host defense against bacteria. S. aureus 
strains possess a capsule composed of polysaccharide.   Strains with serotypes 5 and 8 
show increased virulence in bacteremia, septicemia, and endocarditis (126), (95), (6).  The 
enhanced virulence conferred by the capsule is due to its ability to decrease the uptake of 
bacteria by opsonophagocytosis (126).  Also, pretreatment with antibodies against the 
capsule is protective in endocarditis (74).   
Some staphylococcal proteins target the host complement pathway.  The 
complement system is composed of proteins that are cleaved and activated to coat the 
bacteria and form a membrane attack complex.  The extracellular fibrinogen-binding protein 
(Efb), the Staphylococcus complement inhibitor (SCIN), and staphylokinase (SAK) aid S. 
aureus in evasion by interfering with the action of serum complement proteins (108).  Efb is 
able to bind to complement factor 3 (C3), thereby inhibiting the ability of C3 to coat the 
bacteria (75).  SCIN inhibits C3b formation by binding to the C3 convertases, C4bC2a of 
the classical pathway and C3bBb of the alternative pathway, (108), thereby inhibiting 
bacterial phagocytosis and neutrophil killing. SAK activates plasminogen, which leads to its 
cleavage of the C3b and IgG that may coat the surfaces of bacteria and inhibit 
opsonophagocytosis (108). 
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Neutrophil recruitment is targeted by the chemotaxis inhibitory protein of 
staphylococci (CHIPS) and the extracellular adherence protein (Eap; also known as MHCII 
analogue protein, MAP).  These are secreted proteins that can bind to two targets leading  
to immune evasion.  First, the ability of neutrophils to migrate to the site of infection is 
inhibited by CHIPS binding to the formyl peptide receptor via the amino terminus of CHIPS  
(103).  Also, by binding to the complement factor 5a receptor, CHIPS inhibits the 
chemoattractant C5a from binding to its receptor.  Eap can bind to intercellular adhesion 
molecule-1 (ICAM-1), a ligand for the integrin lymphocyte-function-associated antigen (LFA-
1), which is needed for neutrophil adhesion and, ultimately, extravasation (19).  
 
Staphylococcal vaccine efforts 
 Undoubtedly, the need for a vaccine for S. aureus is dire due to the increased 
number of infections caused by antibiotic resistant strains.  Clinical and basic science 
research on S. aureus has provided the biomedical community with vast amounts of 
knowledge to understand the pathogenesis of S. aureus infections, but generating a 
vaccine for S. aureus is complicated.  First, the bacterium has many virulence factors with 
redundant activities.  Second, the diseases caused by S. aureus are varied. Furthermore, a 
significant proportion of the population is composed of asymptomatic carriers that may not 
develop disease.  Due to their impaired immune status, immunocompromised individuals 
and those at elevated risk for infection, would be optimal candidates for passive 
immunization therapy.  Active immunization would be ideal for individuals with the ability to 
mount an immune response, like healthcare workers.  These factors pose a major 
challenge in deciphering how to best construct a vaccine.   
 Recently, pharmaceutical companies have conducted active and passive 
immunization programs (Summarized in Table 1-1).  Nabi developed StaphVAX, which 
contains capsular antigens, and tested its efficacy in dialysis patients. Although, StaphVAX  
 24 
 
Table 1-1.   Staphylococcus aureus vaccines in clinical trials.  Reprinted from Infectious 
Disease Clinics of North America, 23 (1), AC Schaffer and JC Lee,  Staphylococcal 
vaccines and immunotherapies,  153-171, 2009, with permission from Elsevier Limited 
(112). 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failed phase III trials, it did show protection for a brief period of 3-40 weeks post-vaccination 
(114).  Additionally, the antibodies in Nabi’s AltaStaph vaccine were generated in subjects 
who had been immunized with StaphVax, and these were termed AltaStaph.  AltaStaph 
failed phase II trials on bacteremic patients.  Merck’s V710 vaccine is composed of IsdB 
and has successfully undergone phase I testing (112).  Inhibitex had two anti-ClfA 
preparations; Veronate was an IVIg that failed a phase III trial in neonates, and Aurexis was 
a humanized monoclonal with a successful phase II trial of bacteremic patients.  
Pagibaximab (BSYX-A110) by Biosynexus is a chimeric monoclonal against lipoteichoic 
acid that reduced the rate of developing bacteremia in neonates (133).  Despite these 
efforts, a vaccine has not been approved by the FDA. 
 Preclinical studies have shown promise in developing vaccines against S. aureus 
infections targeted at toxins and surface components.  A tetravalent vaccine composed of 
SdrD, SdrE, IsdA, and IsdB was tested in a murine kidney abscess model, and mice 
immunized with the four components survived challenge with clinical isolates (118). This 
approach is promising, as a vaccine against S. aureus may need to target multiple epitopes 
or proteins.  Efforts to target the α-HL have also shown success preclinically.  Antibodies 
generated to an inactive α-HL mutant (89) protected mice challenged with a lethal dose of 
clinical isolates in a pneumonia model (15).  Furthermore, the mice had less inflammation, 
decreased bacterial burden, and less tissue destruction (15) (14).  These animal studies 
have helped to elucidate potential vaccine candidates by discerning the benefit of 
antibodies against particular virulence factors. 
 
Summary 
Antibiotics are the current treatment for S. aureus infections.  With every wave of 
antibiotic resistance, the medical community has to adapt by using last line of defense 
antibiotics or by combining multiple antibiotics in order to clear the infections.   With CA-
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MRSA infections on the rise, there is a need to abrogate the spread of infections.  Although 
the search for vaccine candidates has resulted in mixed successes, past attempts at S. 
aureus vaccines have indicated that staphylococcal virulence factors can elicit a protective 
response.  By identifying and characterizing the events that occur between the bacteria and 
the infected host, valuable information can be gained about pathogenesis.  This knowledge 
can then be used to develop disease models where the specific virulence factor’s 
contribution can be analyzed.  Also, these types of experiments have helped us to identify 
redundant functions of bacterial proteins.  Conducting epidemiological studies may identify 
correlations between a particular disease and a virulence factor.  These studies may serve 
as guides to identify functions.  Ultimately, the virulence factors can be examined to link the 
epidemiologically associated factor with specific disease models. 
 In this study, a surface and a secreted factor of S. aureus were examined.  First, I 
examined function of a secreted leukotoxin whose presence was associated with strains 
that cause necrotizing pneumonia.  In vitro and in vivo analyses were performed to 
determine its role in disease.  Secondly, an MSCRAMM that is implicated in 
hematogeneous osteomyelitis was studied.  Through biochemical and biophysical assays, I 
identified a novel ligand for the adhesin.  By dissecting the interaction with its ligand, I 
discovered its potential ability to abrogate host coagulation. 
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CHAPTER II 
Panton-Valentine Leukocidin causes necrotizing pneumonia 
 
Introduction 
Analysis of CA-MRSA strains has revealed the presence of the Panton-Valentine 
leukocidin (PVL) (78) (46).  PVL is a secreted toxin that is composed of two protein 
subunits, LukS-PV and LukF-PV, that act synergistically to form pores in the membranes of 
host monocytes, macrophages, and polymorphonuclear cells (20).  PVL belongs to the 
pore-forming toxin (PFT) family that includes α- and γ-hemolysin.  With the exception of α-
hemolysin, the staphylococcal PFTs contain an S subunit (HlgA, HlgC, LukE, LukS-I, LukM, 
and LukS-PV) and an F subunit (HlgB, LukD, LukF-I, LukF’, and LukS-PV) (20).  Identity 
within the subunit classes is high, ranging from 59-79% and 71-79% for S and F, 
respectively, whereas the identity between S and F is only approximately 25% (65) (104).  
Alpha-hemolysin most resembles an F monomer and is the prototypical PFT.  Although the 
sequence identities between PVL and other PFTs are high, PVL is not hemolytic (104) (20).   
Recently, the presence of PVL has been linked to S. aureus strains isolated from 
necrotizing pneumonia patients (78) (46).  Necrotizing pneumonia is characterized by 
massive cell infiltration, severe tissue destruction, and hemorrhage in the air space.  
Etienne and colleagues conducted a study where they discovered that infection by PVL-
positive strains were more common among young, immunocompetent patients (46).  These 
strains caused a fast onset of infection with a high lethality rate.  The authors also analyzed 
lung sections from PVL-positive S. aureus necrotizing pneumonia patients and showed 
overwhelming inflammation in the lungs, as well as the presence of PVL (28, 45).  However, 
it is not known whether PVL is the direct cause for the increased severity of symptoms 
observed in these patients.  
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Neutrophils are often the first cells to respond at the site of infection (44).  They are 
recruited by chemoattractive factors like chemokines, such as interleukin-8 (IL-8), and other 
soluble substances, like leukotrienes and platelet activating factor (106) (135).  IL-8 is a 
chemokine produced and secreted by immune and epithelial cells after activation with 
bacterial determinants or inflammatory cytokines; after secretion, it may last for several 
days.   Increased levels of IL-8 have been shown in bronchial lavages of pneumonia 
patients (106) (107).  In addition to its pore-forming activity, PVL exposure causes 
leukocytes to secrete inflammatory mediators (69).  After PVL treatment, leukocytes have 
been shown to release IL-8, hexosaminidase, lysozyme, β-glucuronidase, IL-8, Leukotriene 
B4, and histamine (70) (20) (137) (68) (58).   
The significance of PVL in CA-MRSA and necrotizing pneumonia S. aureus strains 
was addressed in this study.  We sought to determine whether PVL plays a pivotal role in 
the inflammation observed in necrotizing pneumonia. Specifically, we tested the ability of 
PVL to cause inflammation in lung epithelial cells in vitro and to cause necrotizing 
pneumonia in a mouse model.   
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Materials and Methods 
 
Generation and purification of PVL subunits- In order to generate highly active PVL, each 
subunit was expressed separately, under the control of the native PVL promoter.  The 
plasmids (kindly donated by Francois Vandenesch) were transformed into S. aureus 8325-4 
that was engineered with deletions of hla, hlb, and hlg (kindly donated by Timothy Foster) in 
order to decrease the chance of contamination by other PFTs.  The secreted PVL subunits 
were purified as previously described (104) using cation-exchange chromatography.   
 
Rabbit hemolysis assay- Rabbit erythrocytes (kindly provided by Steven Norris) were 
washed and resuspended in PBS.  A 1% solution of rabbit erythrocyes was incubated with 
increasing concentrations (1-100 nM) of LukS-PV, LukF-PV, or PVL for 60 minutes at 37°C.  
The samples were subjected to centrifugation and the absorbance of the supernatant was 
measured at 525 nm.  
 
Assessment of protein activity- LukS-PV binding to isolated human neutrophils was 
performed using flow cytometry.  A three-color assay was developed that allowed us to 
verify that the neutrophils were pure and that LukS-PV was binding to this population of 
cells.  Neutrophils were incubated with LukS-PV followed by incubation with anti-LukS-PV 
monoclonal antibody conjugated to PE-Cy5.5 (Nabi).  In order to detect the neutrophil 
population, the cells were stained with anti-CD11b-PE and anti-CD15-FITC (R&D Systems). 
Furthermore, we tested the purified subunits for leukotoxic activity.  Briefly, neutrophils were 
incubated with increasing concentrations (0.1-30 nM) of PVL, followed by incubation with 2-
(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium (WST-1) (Roche), a 
tetrazolium salt used for viability determination (124).  The absorbance was measured with 
a Thermo Max plate reader at 650 nm with reference subtraction at 450 nm.  
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IL-8 production by PVL treated epithelial cells- IL-8 induction from PVL-treated epithelial 
cells was measured.  Briefly, A549 cells were seeded overnight, washed, and incubated 
with PBS, PVL (1 nM) , or LPS (100 ng/ml) for 24 hours.  The cells were washed, RNA was 
extracted and reverse transcriptase PCR was performed to detect expression of IL-8.  The 
primers used were 5’-AGCTCTGTGTGAAGGTGCAG-3’ and 5’-
ATTTCTGTGTTGGCGCAGT-3’ for IL-8 and 5’-CCAGGTCTCCTCTGACT-3’ and 5’-
TGCTGTAGCCAAATTCGTTG-3’ for GAPDH, as a control.  Furthermore, secreted IL-8 
was measured from cell-conditioned media using the eBioscience IL-8 sandwich ELISA kit.  
Briefly, A549 cells were seeded overnight, washed, and incubated with PBS, LPS (100 
ng/ml), or increasing concentrations of PVL (10 nM – 10 µM) for 4 hours.  The cell-
conditioned medium was pipetted and debris was pelleted by centrifugation.  All incubations 
were conducted as recommended by the manufacturer. 
 
Pro-inflammatory protein array screen- In order to determine if PVL could induce secretion 
of many pro-inflammatory cytokines, a Panomics protein array was incubated with cell-
conditioned media from PVL-treated lung epithelial cells.  Briefly, A549 cells were seeded 
overnight, washed, and incubated with 30 nM PVL for 24 hours.  The cell-conditioned 
medium was pipetted, and debris was pelleted by centrifugation. All incubations were 
performed according to manufacturer’s instructions. 
 32 
Results 
 
Active PVL subunits were produced. 
 The purity of PVL subunits was confirmed by SDS-PAGE, and Western blotting 
(Figure 2-1a).  Rabbit erythrocytes were incubated with increasing concentrations of 
purified LukS-PV, Luk-PV, or PVL to assess whether the toxin preparation was 
contaminated with other PFTs (Figure 2-1b).  The results confirmed the purity of the PVL 
preparation.  Next, the toxin’s activity on isolated human neutrophils was examined.  Flow 
cytometry binding experiments confirmed that the LukS-PV subunit bound to CD15 and 
CD11b double positive cells (Figure 2-1c).  Furthermore, PVL readily lysed human 
neutrophils, with an LD50 of 250 pM (Figure 2-1d).   
 
PVL-induced inflammation from lung epithelial cells 
 To determine if PVL production by pneumonia-causing S. aureus strains triggered 
inflammatory responses from lung epithelial cells, experiments were performed using in 
vitro cultured A549 cells.   The ability of PVL to stimulate IL-8 production in A549 cells was 
examined.  The cells were incubated with PVL or LPS, as a positive control, followed by 
detection of IL-8 expression using RT-PCR (Figure 2-2a).  The PVL-treated epithelial cells 
produced approximately the same amount of IL-8 as the LPS-treated cells, and untreated 
cells did not produce IL-8, indicating that PVL induced expression of the proinflammatory 
cytokine.  Next, the ability of PVL to induce secretion of IL-8 by A549 cells was examined.  
The cells were incubated with PBS, LPS, or increasing concentrations of PVL (10 nM- 10 
µM), and the cell-conditioned media was harvested.  The concentration of secreted IL-8 
was measured using a sandwich ELISA.  Results showed that PVL-treated A549 cells 
secreted similar amounts of IL-8 as that secreted by LPS-stimulated cells (Figure 2-2b).  
Together, these data indicate that PVL-stimulated A549 cells express and secrete IL-8.  
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Figure 2-1.  The purified Panton-Valentine Leukocidin subunits are active.  (A)  Western 
blots: The LukF-PV (left) and LukS-PV (right) proteins were separated by SDS-PAGE and 
immunoblotted with protein-specific monoclonal antibodies followed by goat-anti-mouse 
IgG.  (B)  Hemolysis assay:  Rabbit erythrocytes were suspended in PBS and incubated 
with increasing concentrations (1-100 nM) of LukS-PV, LukF-PV, or both subunits for 30 
minutes.  Erythrocytes treated with water served as a positive control, and for normalization. 
(C) Flow cytometry:   Isolated human neutrophils were incubated with 0.5 nM LukS-PV 
followed by anti-LukS-PV conjugated to Pe-Cy5.5, anti-CD15-FITC, and anti-CD11b-PE.  
Top panels are controls of the bottom panels.  (D)  Neutrophil viability assay:  Isolated 
human neutrophils were incubated with increasing concentrations (1-100 nM) of LukS-PV, 
LukF-PV, or both subunits prior to the addition of WST-1 for viability determination.   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Figure 2-2.  PVL-induced inflammatory cytokine secretion 
from alveolar epithelial cells.  (A) Induction of IL-8 
expression measured by Reverse-transcriptase PCR:  Lung 
epithelial cells were incubated with PVL, LPS, or untreated 
followed by RNA extraction and RT-PCR with primers for 
IL-8 or GAPDH. (B) Induction of IL-8 secretion by lung 
epithelial cells.  Cells were incubated with PBS, LPS, or 
increasing concentrations (10 nM -10 µM) of LukS-PV, 
LukF-PV, or both subunits.  The IL-8 concentrations of cell-
conditioned medium were determined by sandwich ELISA. 
(C) Panomics inflammatory cytokine protein array: 
Induction of inflammatory cytokine secretion from PVL-
treated lung epithelial cells was determined by incubating 
the array membranes with cell-conditioned medium. 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 To determine if PVL induced the secretion of additional pro-inflammatory mediators, 
a Panomics protein array was used.  A549 cells were treated with PVL and cell-conditioned 
media were collected and used for protein array incubation (Figure 2-2c).  The secretion 
profiles of PVL and control cells were compared.  PVL-treated epithelial cells secreted IL-8, 
the Th2-promoting cytokine IL-4, and the Th1-promoting cytokines IL-12 and Leptin (in 
lesser quantity).  However, PVL failed to induce secretion of eotaxin, IP-10, Rantes, 
granulocyte-monocyte colony stimulating factor, tumor necrosis factor-α, IL-1, IL-3, IL-6, IL-
10, IL-17, MIP-1, and MIP-5.  These results confirmed the secretion of IL-8, and identified 
the ability of PVL to induce secretion of additional cytokines from A549 cells.  
 
PVL-induced necrotizing pneumonia and active immunization in a murine pneumonia 
model 
An acute mouse model of pneumonia was developed and used to determine if 
instillation with PVL causes pneumonia.  In this model, LukS-PV by itself did not cause 
pneumonia, presumably because both of the toxin subunits are required for its pore-forming 
activity.  However, instilling both PVL components resulted in pathology that was 
comparable to that observed in PVL-positive S. aureus infected animals, and PVL-negative 
S. aureus caused minor inflammation (71) (Figure 2-3).  The PVL-instilled mice had severe 
inflammation, vascular leakage, and disrupted alveolar structure.  Additionally, 70% of mice 
instilled with 10 µg of protein died within 24 hours.  These results indicate that both PVL 
subunits are required to cause necrotizing pneumonia.  PVL by itself is sufficient to cause 
lethality in mice and both subunits are required for the toxicity. 
Further studies evaluated the PVL subunits as vaccinogens.  Mice were immunized 
with either PVL subunit and subsequently challenged with a lethal dose of the virulent S. 
aureus USA300 strain (Figure 2-4) (13).  Active immunization with LukS-PV resulted in 
survival of 75% of the mice challenged; whereas 50% of mice immunized with LukF-PV or 
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Figure 2-3. PVL expression enhances the virulence of isogenic S. aureus strains. (A, B, E, F, 
I, and J) Lung histology of mice infected with PVL-positive and PVL-negative strains or 
inoculated with PVL toxin. The sections are representative of at least three separate 
experiments. Scale bar, 100 µm. (C, G, and K) Line graphs indicate weight loss in grams. (C) 
Parental versus PVL phage; *P < 0.001. (G) Parental versus PVL phage; no statistical 
difference observed. (K) Animals inoculated with 3 µg of LukS+F-PV versus 5 µg LukS-PV; 
*P < 0.01 on day 1. (D, H, and L) Mouse survival. (D) Parental and PVL plasmid; (H) PVL 
phage, PVL phage, and PVL phage PVL plasmid; (L) 20 µg or 10 µg of LukS+LukF-PV 
versus 3 µg LukS+LukF-PV or 5 µg LukS-PV, *P <0.0001. Reprinted from Science 315 
(5815), The Staphylococcus aureus Panton-Valentine Leukocidin Causes Necrotizing 
Pneumonia, M Labandeira-Rey, FCouzon, S Boisset, EL. Brown, M Bes, Y Benito, EM 
Barbu, V Vazquez, M Hook, J Etienne, F Vandenesch, MG Bowden, 2007, with permission 
from the American Association for the Advancement of Science (71). 
 
 [Full Reference Citation]. Reprinted with permission from AAAS.. 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Figure 2-4.   Percent survival following intranasal inoculation with Staphylococcus aureus 
USA300. Balb/c mice (total numbers used/group indicated in parentheses) were 
vaccinated subcutaneously with recombinant LukF, LukS, control proteins or adjuvant 
alone prior to infection with 5 × 107 CFUs of S. aureus in a volume of 20 µL. Mouse 
survival was monitored for up to 7 days post-infection.  Reprinted from Clinical 
Microbiology and Infection 15(2), 156-164, EL Brown, O Dumitrescu, D Thomas, C 
Badiou, EM Koers, P Choudhury, V Vazquez, J Etienne, G Lina, F Vandenesch, and MG 
Bowden, The Panton-Valentine leukocidin vaccine protects mice against lung and skin 
infections caused by Staphylococcus aureus USA300, 2008 with permission from John 
Wiley and Sons (13).  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α-HL survived the infection.  These results indicate that the PVL subunits can generate a 
protective response against lethal challenge by PVL-producing S. aureus in a pneumonia 
model.   
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Discussion 
           Due to the increased numbers of MRSA cases, many epidemiological studies have 
been conducted to identify correlations between the presence of potential virulence factors 
with S. aureus-caused diseases.  The pvl genes have been detected in strains that cause 
severe necrotizing pneumonia.  Therefore, we sought to determine whether we could 
experimentally link the presence of PVL in these strains to the severity of disease.   
           In order to study the toxin, recombinant subunits LukS-PV and LukF-PV were 
generated in a S. aureus strain deficient in the expression of  α-, β-, and γ-hemolysins.  The 
toxin preparation was pure, devoid of other toxins and cell-wall components, and was fully 
active towards human neutrophils.  Prior to conducting mouse experiments, in vitro 
experiments with lung epithelial cells were performed, and I detected IL-8 secretion from 
toxin-treated A549 cells.  Results from the mouse model have clearly implicated PVL as a 
cause of necrotizing pneumonia.  An acute model of pneumonia was used to compare the 
virulence of PVL-positive versus PVL-negative strains and PVL protein instillation into the 
mice.  Indeed, the PVL-positive infected mice developed severe pneumonia; whereas, the 
PVL-negative strains caused mild inflammation.  Surprisingly, instilling mice with PVL 
protein alone was sufficient to cause necrotizing pneumonia (71). 
     Furthermore, a vaccine study performed with the PVL subunits showed that mucosal 
vaccination with LukS-PV protein was a successful active immunization strategy, as 
immunized mice showed higher percentage of survival after challenge with a clinical isolate 
than control mice (13).   
           Results from experiments performed with the recombinant PVL toxin combined its 
correlation with strains that cause necrotizing pneumonia.  Necrotizing pneumonia causes 
lung tissue destruction, vascular leakage, and overwhelming inflammation.  In vitro 
experiments conducted with epithelial cells treated with each subunit or both resulted in the 
release of IL-8 from epithelial cells.   
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However, the overwhelming inflammation seen during necrotizing pneumonia 
cannot be solely attributed to PVL-induced IL-8 secretion from airway epithelial cells.  
Instead, the PVL-induced pneumonia was only observed in mice instilled with both PVL 
subunits, suggesting that the toxin’s ability to cause pneumonia may be related to its ability 
to lyse leukocytes. Therefore, the pneumonia is likely due to the toxin’s high activity on 
infiltrating neutrophils and resident alveolar macrophages, and its ability to cause epithelial 
cell inflammation is less of a factor.  To test the contribution of leukocyte inflammation, the 
experiments described herein could be performed on leukocyte-depleted animals.  Previous 
efforts to conduct these experiments resulted in morbidity and mortality of all animals, 
whether infected with PVL-negative or PVL-positive S. aureus, because the leukopenia 
rendered them more susceptible to staphylococcal disease.   
           In conclusion, virulence factors that are correlated epidemiologically with specific 
disease can be studied in vitro and in vivo to link the presence of genes with disease 
causation.  
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CHAPTER III 
The MSCRAMM Bbp targets the Fibrinogen Aα  chain 
 
Introduction 
 S. aureus possesses cell-surface adhesins to aid in the attachment, colonization, 
and invasion of host tissues. The bacteria may also use adhesins or Microbial Surface 
Components Recognizing Adhesive Matrix Molecules (MSCRAMMs) to evade host immune 
responses.  MSCRAMMs can target both extracellular matrix and blood plasma molecules 
and several MSCRAMMs have more than one ligand (Table 3-1).     
  The domain organization and predicted structures of the Sdr subset of the 
MSCRAMMs are similar, although sequence identity among the Sdr proteins may be low.  
One difference among the Sdr proteins is the B-repeat content.  The clumping factors do 
not contain B-repeats, while SdrC has two, SdrD has five, and SdrE and Bbp have three. 
Also, SdrE and Bbp have been described as allelic variants with higher identity between 
these two than among any of the other Sdr proteins.  Many studies have correlated the 
presence of the Sdr proteins in S. aureus isolated from healthy or sick individuals.  Analysis 
of isolates from carriage strains and strains that cause invasive disease revealed that the 
clfA, clfB, and sdrC genes were present in almost all of the isolates, regardless of the 
source.  However, only 38-56% of isolates contained the genes sdrD, SdrE, and bbp (100).  
Interestingly the authors found sdrE in 40% of the carriage isolates and in 56% of the 
strains causing invasive disease; this led to the conclusion that sdrE is preferentially 
associated with invasive strains (100).   
A second study examined the genes encoding for SdrC, SdrD, and SdrE/Bbp in 
carriage and invasive isolates (111). The primers used for this study do not differentiate 
sdrE from bbp.  sdrC was found in all strains; sdrD was associated with MRSA. sdrE/bbp 
was present at similar levels in MSSA and MRSA. Furthermore, the authors concluded that  
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Table 3-1.  Staphylococcus aureus MSCRAMMs with multiple ligands.  
MSCRAMM Ligands 
Protein A 
IgG, von Willebrand Factor, TNFα receptor (TNFR), epidermal 
growth factor receptor (EGFR) 
FnbpA fibronectin, fibrinogen (Fg), elastin 
FnbpB fibronectin, fibrinogen 
ClfA fibrinogen, complement regulator factor I 
ClfB fibrinogen, cytokeratin 10 
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both SdrD and SdrE/bbp may be important in osteomyelitis.  Lastly, when Tristan and 
colleagues evaluated carriage, endocarditis, and hematogeneous osteomyelitis/arthritis 
isolates, they detected bbp (sdrE was not tested) in 21%, 11%, and 38% of the respective 
isolates (127).  These studies indicate that sdrE and bbp may be present in S. aureus 
isolated from carriers and from patients with invasive disease. 
Together, these epidemiological data suggest that the disease with which bbp 
preferentially associates is osteomyelitis.  However, the fact that the isolates in the study by 
Tristan and colleagues evaluated hematogeneous osteomyelitis isolates may indicate a role 
for Bbp in the blood.  Moreover, patients suffering from diabetic osteomyelitis had higher 
titers to Bbp than patients with soft-tissue infections (101).  Furthermore, Bbp studies have 
revealed  bone-sialoprotein (BSP), a major constituent of bone, as a ligand for Bbp binding.  
Therefore, it is a potential staphylococcal virulence factor.  Because several MSCRAMMs 
have multiple ligands, I hypothesized that Bbp may recognize other host proteins. 
Fibrinogen (Fg) is a blood glycoprotein involved in the clotting cascade and cell 
signaling. It is targeted by many MSCRAMMs (Figure 3-1).  It is a dimeric protein composed 
of two Aα, Bβ, and γ chains that are held together by intra- and inter-chain disulfide bonds.  
Additionally, its overall structure has been solved by crystallography; however, the structure 
of the carboxy-terminus of the Aα chain has only been partially elucidated (67) (17).  In 
order to form fibrin, the fibrinopeptides A and B must be cleaved from the amino-terminus of 
the Aα and Bβ chains, respectively, to expose sites that are important for the lateral 
aggregation of protofibrils.  Additionally, the transglutaminase Factor XIIIa catalyzes the 
formation of covalent bonds that crosslink the fibrin fibrils.   
The remarkable domain organization similarity among Bbp and other staphylococcal 
Fg-binding MSCRAMMs prompted further study to determine if a second ligand for Bbp 
exists.  A ligand screen revealed that BbpN2N3 recognizes human Fg.  Therefore, I 
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conducted a series of experiments that localized the binding to residues on Fg Aα that are 
not targeted by other MSCRAMMs.  Bbp on the surface of bacterial cells mediated 
attachment to the mapped residues in Fg Aα.  Furthermore, pretreatment of Fg with 
BbpN2N3 inhibited the formation of fibrin.   
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Figure 3-1.  MSCRAMMs target different sites in the fibrinogen chains.  Cartoon of the separate 
chains indicating the residues targeted by ClfA (γ 395-411), SdrG (Bβ 6-20), and ClfB (Aα 316-328).   
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Materials and Methods 
 
Commercial reagents- Plasminogen, von Willebrand Factor, and fibronectin depleted 
human fibrinogen was from Enzyme Research, human fibronectin was from Chemicon, 
collagen I from rat tail tendons was from Cultrex R&D, recombinant human collagen III was 
from FibroGen.  Bovine serum albumin fraction V (BSA) was from Serological Proteins, Inc.  
Restriction enzymes and T4 ligase were from New England Biolabs.  Isopropyl-beta-D-
thiogalactopyranoside (IPTG) was from Gold BioTechnology, Inc.  Chromatography media 
and anti-His monoclonal antibody were purchased from GE Healthcare unless otherwise 
noted.  Nitrocellulose membrane, goat-anti-mouse-alkaline phosphatase, goat-anti-rabbit-
alkaline phosphatase, and goat-anti-rabbit-horseradish peroxidase were purchased from 
Bio-Rad. Donkey-anti-goat-horseradish peroxidase was from Applied Biological Materials 
Inc.  Superblock, used to block solid-phase assay wells, and NBT/BCIP, for developing 
western blots were from ThermoFisher.  Lysostaphin, Luria broth, SigmaFast OPD, used to 
develop solid phase assays, laminin from Engelbreth-Holm-Swarm murine sarcoma 
basement membrane, collagen IV from fibroblast and epithelial cell co-culture, goat-anti-
human-Fg, bovine neck ligament elastin, and bovine nasal septum collagen II, and 
thrombin were from Sigma. Brain-heart-infusion broth (BHIB) was from Remel.  M17 media 
was purchased from Oxoid.  Oligonucleotides were purchased from IDT.  
 
Media and growth conditions– Escherichia coli strain TOP 10 (Invitrogen) was used for 
subcloning Fg truncation mutants, and strains XL-1 Blue and XL-10 Gold (Stratagene) were 
used for expression of recombinant proteins.  E. coli was cultured at 37°C with shaking 
(250 rpm) in Luria broth supplemented with kanamycin (50 µg/ml) for TOP 10 or ampicillin 
(100 µg/ml) for XL-1 Blue and XL-10 Gold.  Lactococcus lactis was cultured in M17 
supplemented with glucose (0.5%) and erythromycin (5 µg/ml) at 30°C.  Staphylococcus  
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Table 3-2.  Oligonucleotides used in this study.  
Primer name Oligonucleotide sequence 
pQE30-BbpF CCCGGATCCGTTGCTTCAAACAATGTTAATGAT 
pQE30-BbpR CCCAAGCTTTTATTCAGGTTTAACAGTACCGTCACC 
pQE30-FgAα1F CGGGATCC GCAGATAGTGGTGAAGGT 
pQE30-FgAα1-575R CGAAGCTTTTAGGAGTCTCCTCTGTTGTAACT 
pQE30-FgAα1-560R CGAAGCTTTTAGTAACTTGAAGATTTACCACG 
pCU1-BbpPrF CGGGATCCGATATAACATACATCAACAT 
pCU1-BbpTrR CGTCTAGAATATTATCGCCTCATATAAG 
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aureus strains MRSA 252 and Newman derivatives were cultured at 37°C with shaking 
(250 rpm) in Brain-heart-infusion broth (BHIB) supplemented with erythromycin (5 µg/ml), 
tetracycline (2 µg/ml), and/or chloramphenicol (10 µg/ml) as needed.  
 
 Recombinant BbpN2N3 - The N2N3 region of Bbp was cloned according to previously 
described methods (129).  Briefly, S. aureus 024 (kindly donated by C. Ryden) genomic 
DNA was used to amplify the N2N3 sequence using the primers listed in Table 3-2 
corresponding to the N2N3 subdomains of Bbp for digestion with BamHI and HindIII and 
ligation into pQE30.  The plasmid was transformed into XL-1 Blue and sequenced to verify 
its integrity.  This construct was generated by Jenny K. Horndahl in our laboratory.  E. coli-
BbpN2N3 was cultured to exponential phase, induced with 200 µM IPTG, and grown for an 
additional 3 hours.  The cells were pelleted, lysed, and purification of BbpN2N3 was 
accomplished using Ni2+ affinity chromatography as previously described (22) on a HiTrap 
Chelating column.  Fractions were analyzed by SDS-PAGE, pooled, and dialyzed for anion 
exchange-purification using a Q HP Sepharose.  To assess the purity of BbpN2N3, the 
protein was run on 10% SDS-PAGE and stained with Coomassie blue or electrotransferred 
to nitrocellulose.  The membrane was blocked with TBS containing 0.1%Tween-20 (TBST) 
and 1% BSA, and was probed with anti-His monoclonal, followed by anti-mouse-AP.  
BbpN2N3 was further analyzed by mass spectrometry (not shown).  
 
Anti-N1 monoclonal antibody- Mouse monoclonal antibody 8B7 recognizing the N1 
subdomain of the A domain of Bbp was kindly donated by Pietro Speziale. 
 
Rabbit-anti-BbpN2N3 antibodies-  Polyclonal antisera to BbpN2N3 were generated in two 
rabbits at Rockland Immunochemicals under the Fast Production Protocol.  IgG was 
purified using protein A-sepharose (ThermoFisher) affinity chromatography.  Next, the IgG 
 50 
was cleared for crossreactive binding to Sdr proteins before positive affinity purification on 
BbpN2N3 coupled to EZlink beads (ThermoFisher). 
 
Bbp expression from clinical strains-  S. aureus clinical isolate MRSA 252 from blood was 
obtained from Network on Antimicrobial Resistance in Staphylococcus aureus (NARSA).  S. 
aureus TCH 60 and TCH 959 skin and abscess isolates, respectively, were kindly donated 
by Kristina Hulten.  To examine the in vitro expression of Bbp in the strains, overnight 
cultures were diluted 1:100 into fresh BHIB.  Exponential phase cultures were harvested at 
an OD600 of 0.55, 0.6, 0.7,0.8, and 0.9. The cell-wall proteins were harvested by lysostaphin 
extraction as previously described (21).  Subsequently, the proteins were separated on 
SDS-PAGE and electrotransferred to nitrocellulose membrane for Western blotting with 
monoclonal-anti-N1 and polyclonal anti-BbpN2N3 antibodies.   
 
Protein modeling– The predicted structure of BbpN2N3 was modeled based on the solved 
structure of previously crystallized MSCRAMMs (102) (43) using the Ribbons program. 
Structural modeling was performed by Dr. Vannakambadi Ganesh in our laboratory. 
 
BbpN2N3 ligand screen– Binding of BbpN2N3 to various extracellular matrix and plasma 
proteins was determined using an ELISA-type solid-phase assay. BSA, Fg, fibronectin, 
collagen type I-IV, and elastin were coated on microtiter wells at 1 µg per well, and laminin 
was coated at 10 µg per well overnight at 4°C in bicarbonate buffer pH 8.3.  The next day, 
the wells were washed with TBST, blocked and incubated with ten-fold dilutions of BbpN2N3 
(0.1-10 µM), followed by rabbit anti-BbpN2N3 and goat-anti-rabbit HRP for detection of bound 
BbpN2N3.  The wells were developed with SigmaFast OPD, and the absorbance was 
measured at 450 nm with a Thermo Max plate reader (Molecular Devices). 
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Fg binding assay – To detect binding of Fg to Bbp, a solid-phase assay was performed.  
Microtiter wells were coated with increasing amounts of BbpN2N3 (0.25-2.5 µg) overnight in 
bicarbonate buffer pH 8.3.  The next day, wells were washed, blocked, probed with soluble 
Fg (1 µM) and detected with anti-human Fg followed by anti-goat-HRP.  The wells were 
developed, and the absorbance was measured at 450 nm.  
 
Fg species screen – Human, mouse (Enzyme Research), cat, dog, cow, sheep, and pig 
(Sigma) Fg, were coated on microtiter wells at 10 µg/ml overnight in bicarbonate buffer pH 
8.3.  The next day, the wells were washed, blocked, and probed with 500 nM BbpN2N3 and 
ClfAN2N3 followed by mouse anti-His-HRP.  The wells were developed and the absorbance 
was measured at 450 nm. 
 
Surface Plasmon Resonance (SPR) – SPR was performed at 25°C on a BIAcore 3000 
system (GE Healthcare).  Twelve microliters of Fg in 10 mM sodium acetate pH 5.5 (10 
µg/ml) was injected onto an activated CM5 chip surface at a flow rate of 5 µl/min.  
Approximately 1600 Response Units (RU) of Fg were immobilized via amine coupling.  A 
second uncoupled flow cell was activated and deactivated to serve as a reference cell for 
binding experiments.  Increasing concentrations of BbpN2N3 (40 nM-2.56 µM in TBS-0.005% 
Tween 20) were injected to determine the kinetics of the interaction between Fg and 
BbpN2N3.  The reference cell sensorgrams were subtracted from the experimental cell 
sensorgram. BIAevaluation software was used to determine kinetic constants.   Xiaowen 
Liang performed these experiments. 
 
SDS-PAGE and Far Western of Reduced Fg- Laemmli sample buffer containing 10 mM 
dithiothreitol was added to Fg for SDS-PAGE separation.  The gels were either stained with 
Coomassie blue or electrotransferred to nitrocellulose for blotting.  Briefly, the membranes 
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were blocked with TBST containing 1% BSA followed by probing with BbpN2N3 (15 µg/ml), 
ClfAN2N3 (15 µg/ml), or SdrGN2N3 (5 µg/ml).  The bound proteins were detected with anti-His 
monoclonal antibody followed by anti-mouse-AP. 
 
E. coli Fg constructs and C-terminal truncation mutants - E. coli expressing full-length 
recombinant His-tagged Fg chains Aα, Bβ, and γ have been previously described (81) (8, 
9).  Plasmid containing the Fg Aα sequence was used as template to amplify the DNA 
corresponding to mature Aα residues 1-575 and 1-560 using the primers listed in Table 3-2.  
Selected plasmids were digested, the inserts ligated to pQE30, and the plasmids 
transformed into XL-1 Blue cells.  Sequencing was used to verify the integrity of the 
plasmids pQE30-Aα1-575 and pQE30-Aα1-560.  The proteins were expressed and induced 
with 200 µM IPTG as described above for BbpN2N3, purified using Ni2+ affinity 
chromatography in the presence of 8M urea (Sigma), and separated on 10% SDS-PAGE or 
used for binding assays.  
 
E. coli Fg construct solid-phase assays- Fg, recombinant Fg chains, and Aα truncation 
mutants were coated on microtiter wells in bicarbonate buffer overnight.  The wells were 
washed, blocked, probed with BbpN2N3 (15.6-500 nM) and detected with anti-BbpN2N3 and 
anti-rabbit-HRP. The wells were developed and the absorbance was measured at 450 nm. 
 
E. coli Fg construct Far Westerns- Laemmli sample buffer containing 10 mM dithiothreitol 
was added to recombinant Fg constructs and truncation mutants for SDS-PAGE separation 
followed by staining with Coomassie blue or transferring to nitrocellulose.  The membranes 
were blocked with 1% BSA and probed with BbpN2N3 (15 µg/ml) followed by detection with 
anti-BbpN2N3 and anti-rabbit-AP.  
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Table 3-3. Constructs used in this study.  
CONSTRUCT VECTOR RESIDUES SOURCE 
E. coli BbpN2N3 pQE30 270-599 This study 
E. coli SdrGN2N3 pQE30 273-597 (102) 
E. coli ClfAN2N3 pQE30 229-545 (43) 
E. coli Fg Aα pQE30 
Full length mature 
Aα 
(81) 
E. coli Fg Aα1-575 pQE30 1-575 of mature Aα This study 
E. coli Fg Aα1-560 pQE30 1-560 of mature Aα This study 
E. coli Fg Bβ pQE30 
Full length mature 
Bβ 
(8) 
E. coli Fg γ pQE30 Full length mature γ (9) 
L. lactis-vector pKS80 Empty vector (21) 
L. lactis-Bbp pKS80 Full length Bbp This study 
S. aureus Newman 
bald-vector 
pCU1 Empty vector (21) 
S. aureus Newman 
bald-Bbp 
pCU1 
Full length Bbp (with 
promoter and 
terminator) 
This study 
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Lactococcus lactis-Bbp1615- The entire bbp coding region from strain S. aureus B504 
(kindly donated by Ed Feil) was ligated into the pKS80 plasmid for constitutive expression.  
The plasmid was transformed into Lactococcus lactis MG1363.  This complemented strain 
expresses Bbp on the surface of L. lactis under a constitutive promoter and was kindly 
provided by Timothy Foster.  
 
S. aureus Newman bald-Bbp – The strain S. aureus DU6023 clfA5 isdA clfB::Emr 
ΔsdrCDE::Tcr (21) will be referred to as Newman bald and was used for expression of full-
length Bbp on the surface of the bacteria under the control of its native promoter as 
previously described for other MSCRAMMs (21).  Briefly, the DNA was amplified from S. 
aureus MRSA252 (kindly provided by NARSA) using the primers listed in Table 3-2, and 
subcloned into TOPO-Zero Blunt (Invitrogen) for transformation into E. coli TOP 10 cells.  
The plasmid was digested with BamHI and XbaI; the insert was ligated to the shuttle vector 
pCU1, and the plasmid was transformed into XL-10 Gold cells (Stratagene).  Sequencing 
was used to verify the integrity of the plasmid pCU1-Bbp.  The plasmid was purified and 
transformed into electrocompetent S. aureus 8325-4 and plated on BHIB with 
chloramphenicol. Subsequently, pCU1-Bbp was electroporated into electrocompetent 
Newman bald cells.  
 
Bacterial adherence assays:  Binding of L. lactis-Bbp or Newman bald-Bbp to the Fg Aα 
truncation mutants was tested in crystal violet adherence assays.  Microtiter wells were 
coated with Aα1-575 and Aα1-560 in bicarbonate buffer overnight.  The next day, the wells 
were washed with phosphate-buffered saline (PBS), blocked with PBS-1%BSA, and 
washed with PBS supplemented with 0.5 mM magnesium chloride and 0.1 mM calcium 
chloride (PBS-Ca2+-Mg2+).  L. lactis-Bbp and L. lactis-vector were grown overnight, washed 
in PBS-Ca2+-Mg2+, and resuspended in PBS-Ca2+-Mg2+ at an OD600 of 1.0.  Newman bald-
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Bbp and Newman-bald vector were grown overnight, diluted 1:50, and grown to an OD600 of 
0.6.  The cells were washed and resuspended to an OD600 of 2.0 in PBS-Ca2+-Mg2+.  The 
blocked and washed wells were incubated with 0.1 ml of bacterial suspension for 1.5 hours 
at 30°C for L. lactis or 37°C for Newman bald strains.  The wells were washed with PBS-
Ca2+-Mg2+, then fixed with paraformaldehyde (4%) for 30 minutes.  After washing with PBS-
Ca2+-Mg2+, the wells were incubated with crystal violet (0.5%) for 3 minutes.  The wells were 
washed and the crystal violet was dissolved in acetic acid (5%).  The absorbance of the 
wells was measured at 590 nm.   
 
Synthetic peptides- Fg Aα peptides (Table 3-4) corresponding to the human sequences 
551-575, 561-565, 556-570, 551-565, and a scrambled 51-575 were synthesized by 
Biomatik.  
 
Isothermal titration calorimetry (59)- The interaction between BbpN2N3 protein and soluble 
Fg Aα 15mer or 25mer peptides (Table 3-4) was analyzed using a VP-ITC microcalorimeter 
(MicroCal) at 30°C.  The cell contained 15 µM BbpN2N3 and the syringe contained 225 µM 
peptide in TBS.  All samples were degassed for 5 min. The titration was performed with a 
stirring speed of 300 rpm.  The initial injection was 5 µl followed by 29 injections of 10 µl 
with an injection speed of 0.5 µl/second. Data were fitted to a single binding site model and 
analyzed using Origin version 5 (MicroCal) software. 
 
Inhibition assay- BbpN2N3 (150 nM) was incubated with increasing concentrations of Fg Aα 
peptides (0.1 to 30 µM) for 30 minutes before incubation in Fg coated wells.  The wells 
were incubated with rabbit-anti-BbpN2N3 and goat-anti-rabbit-HRP. The wells were 
developed with SigmaFast OPD (Sigma), and the absorbance was measured at 450 nm 
with a Thermo Max plate reader (Molecular Devices). 
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Table 3-4.  Peptides synthesized for this study  
Peptide name Peptide sequence 
Fg Aα 551-575 FPSRGKSSSYSKQFTSSTSYNRGDS 
Fg Aα Scrambled GSSQTSKTSDFPRRYFSSKSYGNSS 
Fg Aα 551-565 FPSRGKSSSYSKQFT 
Fg Aα 556-570 KSSSYSKQFTSSTSY 
Fg Aα 561-575 SKQFTSSTSYNRGDS 
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Fibrin inhibition assay- Using the previously described methods (22), thrombin-catalyzed 
fibrin formation was studied.  Briefly, Fg coated wells were incubated with increasing 
concentrations of BbpN2N3, SdrGN2N3, or BSA for 30 minutes prior to the addition of 1.0 NIH 
unit of thrombin per milliliter.  The turbidity of the wells was measured at 405 nm. 
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RESULTS 
 
Bbp is expressed in clinical isolates. 
The presence of bbp has been correlated with both carriage and invasive S. aureus 
isolates. In order to study the expression of Bbp from a clinical isolate, I obtained MRSA 
252, which is a blood S. aureus isolate.  The cell-wall proteins were harvested from 
exponentially growing cultures using lysostaphin digestion.  Western blotting the extract 
with anti-N1 monoclonal antibody revealed the presence of an approximately 175 kDa 
protein, corresponding to full-length Bbp (Figure 3-2).  The Western blot also shows another 
band of approximately 50 kDa which is the detection of Protein A in the cell-wall extract.  
Next, I probed the cell-wall extraction with an anti-BbpN2N3 affinity-purified polyclonal.   
Western blotting with the N2N3 polyclonal antibody identified two bands of approximately 
100 kDa and 175 kDa in all of the samples (Figure 3-2).  In other Sdr proteins, cleavage of 
the N1 domain by a metalloprotease has been documented (87). Therefore, the higher 
band is the full-length Bbp, and the lower band is likely to be a form of the protein that is 
missing the N1 domain. Also, Western blots with the N2N3 polyclonal showed a faint band 
of lower molecular weight (approximately, 80 kDa) in early time points only (OD600 of 0.55 
and 0.6).  These results indicate that Bbp can be detected in vitro in a blood isolate. 
 
BbpN2N3 binds to human fibrinogen.  
To test the binding of Bbp to putative ligands, a construct that contains the putative 
binding sites, the N2N3 domains, was designed (Figure 3-3).  This construct was expressed 
as a His-fusion protein and purifed with affinity and ion-exchange chromatography (Figure 
3-4). 
An initial screen was performed to examine the binding of recombinant His-tagged 
BbpN2N3 (Figure 3-5a) in a solid-phase assay. Soluble BbpN2N3 (0.01 to 10.0 µM) was used  
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Figure 3-2.  In vitro expression of Bbp.  S. aureus MRSA 252 cells were harvested  
at OD600 = 0.55, 0.60, 0.70, 0.80, and 0.90 and the cell-wall proteins were extracted 
with lysostaphin digestion.  The extract was separated by SDS-PAGE, transferred to 
nitrocellulose and blotted with anti-N1 domain monoclonal antibody (A) or anti-
BbpN2N3 affinity purified polyclonal antibody (B).  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Figure 3-3.  BbpN2N3 construct.  (A) Domain organization of full length Bbp (top) and BbpN2N3 
(bottom) showing the (S) signal sequence, (N1, N2, N3) amino terminal subdomains of A 
region, (B1, B2, B3) B-repeats, (SD) Serine-Aspartate repeat region, (W) wall domain, (M) 
membrane domain, (C) carboxy-terminus.  In BbpN2N3, (H) Hexahistidine tag.  (B)  Structural 
model of the N2N3 subdomains of Bbp based on the structure of other MSCRAMMs.  Beta-
sheets are depicted in yellow.  The N2 domain is at the bottom of the image, and the N3 
domain is at the top. 
 
 
A 
 
 
 
 
B 
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Figure 3-4.  Purified BbpN2N3.  (A)  Coomassie stained recombinant BbpN2N3 (1 
µg/lane).  (B)  Anti-His monoclonal immunoblot of purified BbpN2N3.  
 
 
   A  B        
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to probe microtiter wells coated with extracellular matrix and plasma proteins, followed by 
detection with polyclonal anti-BbpN2N3 and HRP conjugated anti-rabbit polyclonal.  In this 
assay, BbpN2N3 recognized Fg in a concentration-dependent, saturable manner but failed to 
bind to Elastin, Collagen type I – IV, Laminin, Fibronectin, and BSA.  To determine if soluble 
Fg could bind to immobilized BbpN2N3 I performed the reverse assay.  Wells coated with 
increasing amounts of BbpN2N3 (0.25-2.5 µg) supported Fg binding (Figure 3-5b).  These 
results provide evidence for dose-dependent saturable binding between BbpN2N3 and Fg.  
Next, I studied the specificity and affinity of the BbpN2N3-Fg interaction.  First, the 
species tropism of Bbp was examined using solid-phase assays.  Wells coated with Fg 
purified from human, cat, dog, cow, sheep, mouse, and pig were probed with BbpN2N3.  Our 
results indicate that BbpN2N3 only binds to Fg isolated from human plasma (Figure 3-6).   
This is in contrast to the Fg-binding activity of ClfAN2N3, which exhibits a wider host tropism.   
These results suggest that Bbp does not recognize a motif present in Fg from different 
species but one that is specific to human Fg. 
The dissociation constant of BbpN2N3 for Fg was examined using SPR.  Binding of 
BbpN2N3 (40 nM-2.56 µM) to Fg immobilized on a sensor chip was analyzed using a BIAcore 
3000 (Figure 3-7a).   The equilibrium analysis revealed a KD of 540 +/- 7 nM of BbpN2N3 to 
Fg (Figure 3-7b).  Together, these data suggest that human Fg is a second ligand for 
BbpN2N3. 
 
BbpN2N3 recognizes the Aα chain of fibrinogen. 
In order to determine whether Bbp targets one or multiple Fg chains, I used Far 
Western analysis.  Fg was reduced in sample buffer containing β-mercaptoethanol to 
dissociate the disulfide bonds that hold the two sets of three polypeptide chains together 
and separated on SDS-PAGE (Figure 3-8a) followed by transferring to nitrocellulose 
membrane for Far Western probing.  In this assay, BbpN2N3 bound to the Aα chain of Fg,  
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Figure 3-5.  BbpN2N3 binding to Fg. (A)  Ligand screen .  Putative ligands were coated 
on microtiter wells and probed with increasing concentrations (0.1-10 µM) of 
BbpN2N3 followed by rabbit-anti-BbpN2N3 and goat-anti-rabbit-HRP. (B)  Increasing 
amounts of BbpN2N3 (0.25 to 2.5 µg) were coated on microtiter wells and probed 
with 1 µM Fg followed by goat-anti-human Fg and donkey-anti-goat-HRP.   
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Figure 3-6.  Fg species screen.  Microtiter wells were coated with 1 µg of 
human, canine, feline, bovine, ovine, murine, or porcine Fg, or BSA in 
bicarbonate buffer overnight.  The wells were probed with 500 nM BbpN2N3 
or ClfAN2N3, followed by protein specific rabbit polyclonal antibodies and 
goat-anti-rabbit-HRP.  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Figure 3-7.  BbpN2N3 Surface Plasmon Resonance.   Two-fold linear dilutions 
(2.56 to 0.04 µM ) of BbpN2N3 were injected over the Fg immobilized on a Biacore 
sensor chip.  (A) Response curves for each injection of BbpN2N3 (Black) are 
overlaid with the global fitting to a 1:1 binding model (Red).  Kinetic parameters 
were obtained from the fitting.  (B) Equilibrium analysis:  Responses at 
equilibrium of the SPR curves were fit to a one-site binding isotherm to obtain 
the affinity and binding maximum.  Experiment performed by Xiaowen Liang. 
 
A 
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while the previously characterized MSCRAMMs SdrGN2N3 and ClfAN2N3 bound to the Bβ and 
γ chains, respectively (Figure 3-8b).  
In order to verify our Far Western results obtained with reduced Fg, I tested binding 
of BbpN2N3 to the individual Fg chains.  Recombinant full-length Aα, Bβ, and γ were 
expressed as His-tagged constructs and purified (Figure 3-9a).  Individual chains were 
immobilized on microtiter plates and probed for BbpN2N3 (15.6-500 nM) binding using a 
solid-phase assay (Figure 3-9b).  The Bβ and γ chains did not support binding, whereas 
BbpN2N3 bound saturably in a concentration-dependent manner to plasma Fg and Aα.  
Together, these results indicate that BbpN2N3 binds to a site localized to the human Fg Aα 
chain. 
 
The binding site of Bbp lies within residues 561-575 of the Fg Aα chain.  
To map the Bbp N2N3 binding site, I used a systematic approach and constructed C-
terminal truncates of the Aα chain (Figure 3-10a).  The recombinant Fg Aα1-575 and Fg 
Aα1-560 were purified (Figure 3-10b lanes 3 and 4, respectively) and examined for binding 
activity.  Far western blots revealed that Aα1-575 retained the BbpN2N3 binding site; 
however no binding was detected to Aα1-560 (Figure 3-10b), suggesting that no residues 
N-terminal to 561 are necessary for binding.  To further confirm our results, a solid phase 
assay comparing the binding of BbpN2N3 to Aα1-560 and Aα1-575 revealed that only Aα1-
575 could support saturable, concentration-dependent binding (Figure 3-11a).  These 
results indicate that the residues that mediate binding of BbpN2N3 to Fg lie in the Aα chain 
between 561 and 575. 
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Figure 3-8.  Reduced Fg Far Western.  Fg was reduced and separated on SDS-
PAGE followed by Coomassie staining (A) to reveal the three chains Aα (top band), 
Bβ (middle band) and γ (bottom band) or electrotransferred for Far Western blotting 
(B).  Membranes were probed with BbpN2N3 (left), SdrGN2N3 (middle), and ClfAN2N3 
(right). Followed by incubation with protein-specific rabbit polyclonals and goat-anti-
rabbit-AP. 
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Figure 3-9.  Purified individual Fg chains.  (A)  Coomassie stained gel showing the 
individually expressed and purified His-tagged Fg chain constructs compared with 
reduced human Fg (left).   (B)  Fg , and recombinant individual Aα, Bβ, and γ chains 
were coated on microtiter wells overnight in bicarbonate buffer.  They were probed 
with BbpN2N3 followed by anti-BbpN2N3 and goat-anti-rabbit-HRP. 
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Figure 3-10.  Aα truncation mutants.   Cartoon schematic of the full-length and 
truncated Aα chain constructs.  (B) Coomassie stained gel of Fg, recombinant Aα, Aα 
1-575 and Aα 1-560, Bβ, and γ (top) and BbpN2N3 Far Western (bottom). 
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Full-length Bbp binds to Fg Aα chain residues 561-575. 
The apathogenic bacterium Lactococcus lactis has been successfully used as a 
heterologous host for full-length MSCRAMM cell surface display (21).  Therefore, I 
employed this method to determine whether Bbp expressed on the surface of a cell could 
recognize the mapped residues.  Using a bacterial adherence assay, I determined that L. 
lactis-Bbp bound to plates coated with Aα1-575; whereas the empty-vector construct L. 
lactis-pKS80 did not bind to Aα1-560 or Aα1-560 coated wells (Figure 3-11b).  This result 
indicates that full-length Bbp exhibits binding to the mapped residues.  
The S. aureus Newman bald strain lacks surface expression of the MSCRAMMs 
ClfA, ClfB, IsdA, IsdB, SdrC, SdrD, and SdrE (21).  Therefore, this strain was used to 
introduce full-length bbp under the control of its native promoter.  The strains Newman bald-
pCU1 and Newman bald-Bbp were assessed for binding to Aα1-575 and Aα1-560 in an 
adherence assay.  Newman bald-Bbp only adhered to wells coated with Aα1-575 in 
contrast to the empty vector control, which did not recognize either Aα construct (Figure 3-
11c).  The data gathered with L.lactis-Bbp and Newman-bald-Bbp mimic the binding profile 
exhibited by recombinant Bbp N2N3.  These data indicate that Bbp on the surface of 
staphylococcal bacteria can mediate binding to human Fg.   
 
Characterization of the interaction between Bbp and peptides from Fg Aα. 
In order to determine the affinity of the interaction between BbpN2N3 and Fg Aα 
peptides, ITC was performed.  Peptides (225 µM) in TBS were titrated into a cell containing 
15 µM Bbp N2N3 that had been dialyzed into TBS (Figure 3-12).  The one binding site fit 
model was used to analyze the data, which is summarized in Table 3-5.  ITC analysis 
showed that the peptides Aα551-575 and Aα561-575 bind to Bbp N2N3 with a KD below 1 
µM, indicating high-affinity binding.  Furthermore, no binding was detected from the peptide  
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Figure 3-11.  Full-length and BbpN2N3 binding to Aα truncation mutants.   (A) Aα 1-575 and 
Aα 1-560 coated wells were probed with increasing concentrations (15-500 nM) of BbpN2N3, 
followed by anti-BbpN2N3 antibody and anti-rabbit-HRP; (B) stationary-phase L. lactis-pKS80 
and L. lactis-pKS80-Bbp, and (C) exponential-phase S. aureus Newman bald-pCU1 and S. 
aureus Newman bald-pCU1-Bbp.  
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Table 3-5.  Isothermal Titration Calorimetry data  
 N K ΔH 
(kcal/mol) 
ΔS 
(kcal/mol) 
Kd (calc) 
551-575 2.074 1.256E6 -1.269E4 -13.95 0.796 µM 
Scrm 2.633 1.965E5 -8.296E3 -3.149 5.089 µM 
551-565 N.D.  N.D.  N.D.  N.D.  N.D.  
556-570 1.894 5.477E5 -1.039E4 -8.030 1.825 µM 
561-575 1.902 3.227E6 -1.222E4 -10.51 0.309 µM 
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Figure 3-13.  Peptide inhibition.  (A)  BbpN2N3 (150 nM) was preincubated with 
increasing concentrations (0.1 – 30 µM) of peptides prior to incubation in Fg-coated 
wells. (B)  Chart showing the peptide sequences and relative inhibition scores. 
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Figure 3-14.  Alignment of sequences from several species corresponding 
to human Aα 561-575.  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Aα551-565, suggesting that these residues are not important for binding, and further 
strengthening our data with the truncated Fg Aα chain mutants.  The peptide Aα 556-571 
exhibited binding with a KD of 1.8 µM.  Therefore residues contained in this peptide can 
mediate binding to BbpN2N3 albeit with less affinity.  Truncation analysis experiments 
together with ITC indicate that BbpN2N3 binds specifically to Aα residues 561-575.  
To further characterize the binding specificity of BbpN2N3 to Fg, I performed inhibition 
experiments with the synthetic Fg Aα peptides.  BbpN2N3 was preincubated with increasing 
concentrations of peptides (0.1-30 µM) before addition to Fg coated wells in a solid-phase 
assay (3-13a).  The Aα551-575, Aα561-575, and Aα556-570 peptides fully abolished 
binding of BbpN2N3 to Fg.  The scrambled peptide showed partial inhibition of binding, which 
did not reach 100% inhibition.  Additionally, the Aα551-565 peptide could not inhibit the 
interaction.  The results obtained from the inhibition assays are in direct accordance with 
the data gathered in ITC experiments, meaning that the inhibitory activity imparted by the 
peptides is directly related to their ability to bind to BbpN2N3 (Figure 3-13b).  
A Clustal alignment of the Fg Aα 561-575 of Fg from many species was performed 
(Figure 3-14).  The results indicate that the sequence of human, canine, and feline 
fibrinogen are related. All three contain the second Aα RGD site; whereas only part of the 
residues are present in porcine or bovine Fg.  Furthermore, I observed that the rat and 
murine sequences are distant from the human.  These species do not contain the RGD site, 
nor a stretch of polar, uncharged residues.  The alignment data indicate that the feline and 
canine Fg are the closest to human.  The canine and human sequences only differ by two 
residues, yet canine Fg does not support binding of Bbp. 
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Bbp inhibits fibrin formation 
In order to examine the consequences of Bbp binding to Fg, I studied its effect on 
fibrin formation.  Fg-coated wells were pretreated with increasing concentrations of BbpN2N3, 
SdrGN2N3, a Fg-binding MSCRAMM of S. epidermidis, as a positive control, or BSA as a 
negative control prior to addition of thrombin.  BbpN2N3 inhibited the formation of fibrin in a 
concentration-dependent manner, and similarly to SdrGN2N3 (Figure 3-15a).  Human 
thrombin is capable of cleaving the Fg of other species.  Therefore, I examined whether the 
effect on fibrin formation exerted by Bbp was species specific.  The data show that BbpN2N3 
cannot inhibit thrombin-catalyzed fibrin formation from ovine Fg (Figure 3-15b).  Our results 
indicate that pre-treatment of Fg with Bbp inhibits thrombin-catalyzed fibrin formation. 
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Figure 3-15.  Inhibition of fibrin formation.  Increasing concentrations (0.03 – 10 µM) (A) 
or 1 µM (B) of BSA, SdrGN2N3, or BbpN2N3 were preincubated in human Fg-coated (A and 
B) or ovine Fg-coated (B) wells prior to the addition of α-thrombin. 
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Discussion 
 S. aureus uses a multitude of virulence factors to cause a wide range of diseases. 
The MSCRAMMs can mediate binding of S. aureus to host proteins, thereby facilitating 
colonization.  MSCRAMMs, including the Sdr family of proteins, are capable of recognizing 
many ligands.  Here, the identification of human Fg Aα as a second ligand for Bbp is 
reported.   
The data indicate that a strong interaction occurs between the two proteins.  I 
observed that BbpN2N3 was capable of binding to immobilized as well as reduced Fg, and 
recombinant, denatured Fg Aα chain, which is typical of Fg-binding MSCRAMMs (Figure 3-
5a, 8b, 10b, 11).  These data indicate that the MSCRAMM binds to a linear sequence in the 
ligand.  Furthermore, Biacore experiments with immobilized Fg resulted in a KD of 540 nM, 
(Figure 3-7) and the KD generated from ITC with peptide Aα561-575 was 309 nM (Figure 3-
12).  The affinities gathered with the two methods have similar values.  It is possible that the 
affinity was lower in Biacore experiments due to the immobilization of Fg, as this may have 
hidden or obscured the available binding site for BbpN2N3.  Additionally, ITC was performed 
with both the peptide and the protein in solution, with stirring, and in a 5°C warmer 
atmosphere.  Therefore, the experimental conditions in ITC may have been more conducive 
to the binding events between BbpN2N3 and the Aα peptides. 
Also speaking to the specificity of the interaction is that Bbp only targets human Fg 
(Figure 3-6).  Alignment of the sequences corresponding to the human Fg Aα561-575 
revealed small differences among the residues present in human, feline, and canine Fg 
(Figure 3-14).  Specifically, the canine sequence contains an extra hydrophobic residue at 
position 565.  This offsets the stretch of polar, uncharged residues found between 565 and 
571 by one position.  Also, Ser569 in humans is a Thr in the canine sequence.  Although 
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these are the only two differences between the human and canine sequences, they are 
enough to abrogate BbpN2N3 binding to canine Fg. 
The results obtained with recombinant BbpN2N3 were confirmed using constructs that 
express the full-length protein on the surface of two heterologous hosts.  L. lactis and S. 
aureus Newman bald provided a platform to study the binding contribution from a single 
MSCRAMM in prior studies (21).  In this study, Bbp on the surface of both bacteria 
mediated attachment to immobilized Aα1-575 but not to Aα1-560 (Figure 3-11b, c).  These 
data indicate that the full-length protein under the control of its native promoter can lead to 
Fg adherence.  
The binding site of BbpN2N3 was mapped to Aα561-575, which ends with the second 
RGD site of the Aα chain. Reports have suggested a role for the second Aα RGD in binding 
to the integrins α5β1 and αVβ3 (120) (119).  Although further studies are required in order to 
determine what downstream effects occur upon Bbp binding to Fg, one possible effect 
could be the abrogation of the Fg Aα-integrin interaction.  
The effects of the Bbp-Fg interaction on clotting were examined.  We detected an 
abrogation of fibrin formation when Fg was preincubated with Bbp.  The residues Aα561-
575 to which we have mapped Bbp binding lie in the αC domain of Fg.  This domain may 
mediate binding between fibrils to form fibrin.  Also the residues are adjacent to a proposed 
transglutaminase target (116).  Further experiments will determine the effects of Bbp 
binding on lateral association of fibrin monomers into crosslinked fibrin.  
BSP was previously described as a ligand of Bbp, and this interaction may play a 
specific role in facilitating S. aureus osteomyelitis.  Osteomyelitis is an infection of the bone, 
which may be accompanied or caused by hematogeneous spread.  It is possible that Bbp 
may function in two capacities: as an important factor in osteomyelitis and as a contributing 
factor in S. aureus hematologic diseases, such as sepsis.  Future studies regarding the 
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expression profile of Bbp in certain disease settings or disease-specific models may aid in 
elucidating the contribution of Bbp to S. aureus pathogenesis. 
Fg was identified as a novel ligand for the MSCRAMM Bbp.  The binding site was 
mapped to the residues 561-575, which represents a novel MSCRAMM target in Fg.  Also, 
the interaction of Bbp with Fg inhibits the formation of fibrin.  Future studies will further 
define the consequences of Bbp binding to Fg. 
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CHAPTER IV 
Binding mechanism of Bbp to fibrinogen 
 
Introduction 
The binding that occurs between MSCRAMMs and their ligands has been shown to 
be a dynamic event that can result in conformational changes.  This is the case for the 
fibronectin-binding MSCRAMMs of Borrelia burgdorferi, Streptococcus pyogenes and S. 
aureus (105) (113).  The Fnbps from these bacteria form a tandem-beta zipper upon ligand-
binding.  Also, the collagen adhesins, Cna and Ace from S. aureus and Enterococcus 
faecalis, respectively, bind to their ligand through the collagen hug model (142) (80).  The 
S. epidermidis fibrinogen-binding protein, SdrG binds via the dock, lock, and latch (DLL) 
model (102).  Furthermore, ClfA binds to Fg via a variant of the DLL mechanism (43).  
Evidence gathered from alanine scanning, truncation analysis, peptide studies, and 
crystallization has permitted the elucidation of the binding mechanisms of MSCRAMMs.   
The A region of SdrG, ClfA, Cna, and Ace is subdivided into immunoglobin-like N 
subdomains and contains the ligand-binding domains.  The collagen-binding MSCRAMMs 
have a ligand-binding pocket between the N1 and N2 subdomains; whereas, the ligand-
binding site of fibrinogen-binding MSCRAMMs is located between the N2 and N3 
subdomains.   
The dock, lock, and latch mechanism of SdrG binding to the Fg Bβ was elucidated 
using biochemical and structural assays.  In the unbound, apo-SdrGN2N3 structure the 
MSCRAMM is in an open conformation with an unoccupied ligand-binding trench.  A co-
crystal of the complex formed by SdrGN2N3 with the Bβ6-20 peptide showed that the 
MSCRAMM is in a closed conformation after ligand binding (102).  In the latter structure, 
the N3 extension, or latch, is inserted into the N2 domain and forms a complemented β-
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sheet (102).  Additionally, the co-crystal provides information about the interacting residues 
in both the MSCRAMM and the peptide. 
To provide more evidence for the DLL, experiments were performed with truncation 
mutants.  The SdrGN2N3 was truncated to determine that the latching event was necessary 
for ligand binding.  Furthermore, the open and closed conformations were covalently 
engineered by the insertion of cysteine residues into SdrGN2N3 (10).  Because the Sdr 
proteins are similar in domain organization and folding, the dock, lock, and latch 
mechanism of binding has been proposed for this family of MSCRAMMs. 
The collagen hug model of Cna and Ace (from Enterococcus faecalis) is similar to 
DLL.  One striking difference is that the N1 and N2 domains have a longer linker region that 
accommodates the collagen triple helix.  Upon ligand binding, Cna and Ace wrap around or 
“hug” the collagen peptide.  The N1, linker, and N2 ultimately form a tunnel where the 
collage peptide is bound (142).  Similar studies to those performed for SdrGN2N3 with 
constructs that are permanently open or closed, or that have mutations in the C-terminal 
extension or “latch” were used in experiments to support the collagen hug binding 
mechanism (Figure 4-3) (80). 
 Bbp is an MSCRAMM implicated in S. aureus osteomyelitis.  It has been 
demonstrated that Bbp binds to bone-sialoprotein, a component of bone and dentin.  
Because targeting multiple ligands is a common trait among previously characterized 
MSCRAMMs, I determined whether Bbp followed this trend.  In previous studies I identified 
the binding site of Bbp on human Fg Aα.  Importantly, Fg binding from full-length Bbp 
expressed on the surface of heterologous hosts was detected (Figure 3-11).  The binding 
residues on the Fg Aα chain include an RGD site, which suggests that the binding of Bbp 
may inhibit normal fibrinogen signaling (Figure 3-14).  Furthermore, I determined that Bbp 
inhibits fibrin formation (Figure 3-15).  MSCRAMMs use dynamic mechanisms to bind to 
their ligands.  Sequence similarity and structural modeling suggest that of BbpN2N3 may bind 
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to fibrinogen in the same fashion as other MSCRAMMs.  I sought to decipher the binding 
mechanism between Bbp and fibrinogen. 
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Materials and Methods 
Commercial reagents: The reagents used for this chapter are described in Chapter II. 
 
Design of BbpN2N3 mutants by MSCRAMM comparison -  Clustal sequence alignment was 
performed on the amino acid sequences corresponding to the N2N3 domains of Bbp, SdrG 
and ClfA, and the structure of BbpN2N3 was modeled based on solved MSCRAMM 
structures using Ribbons (Chapter III, Figure 3-3).  The Bbp lock truncation is at Ile583 and 
the Bbp latch residues begin at Ser589.  A disulfide bond mutant was constructed with the 
substitutions E376C and P598C.   
 
BbpN2N3  mutants- S. aureus MRSA 252 genomic DNA was used as template to amplify the 
DNA corresponding to Bbp 270-582 (ΔLock and latch) and 270-588 (ΔLatch), and 270-599 
E376C / P598C sequences using the primers listed in Table 4-1.  The products were 
subcloned into TOPO Zero Blunt vector and transformed into TOP3 cells.  After sequence 
verification, the plasmids were digested and inserts were ligated into pQE30 for 
transformation into XL1 Blue cells.  E. coli-BbpN2N3ΔLock, E. coli-BbpN2N3ΔLatch, and E. coli-
BbpN2N3E376C/P598C (BbpCys-Cys) were cultured to exponential phase, induced with 200 
µM IPTG, and grown for an additional 3 hours.  The cells were pelleted, lysed, and 
purification of mutants was accomplished using Ni2+ affinity chromatography as previously 
described (22) on a HiTrap Chelating column   Fractions were analyzed by SDS-PAGE, 
pooled, and dialyzed for anion exchange-purification using a Q HP Sepharose.  To assess 
purity, the proteins were run on 10% SDS-PAGE and stained with Coomassie blue.   The 
BbpCys-Cys construct was run under both nonreducing and reducing conditions to verify 
the formation of a disulfide bond.  The nonreduced sample appeared smaller than the 
reduced sample.  
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Table 4-1.  Oligonucleotides used in this study  
Primer name Oligonucleotide sequence 
pQE30N2N3For CGGGATCCGTTGCTTCAAACAATGTTAAT 
pQE30LockRev CGAAGCTTTTAAGTATTAGTGTAACCTGCATA 
pQE30LatchRev CGAAGCTTTTAGTCAGTAGTTGATAAAATAGT 
Bbp376CRev GACATTCTCACATCTATCAAC 
Bbp376CFor GTTGATAGATGTGAGAATGTC 
Bbp598CRev CCCAAGCTTTTATTCAGGTTTACAAGATACCGCAC 
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Solid-phase binding assays-  Fg was coated on microtiter wells overnight in bicarbonate 
buffer at 10 µg/ml.  The wells were blocked with Superblock and probed with increasing 
concentrations (0.1 – 10 µM) of BbpN2N3, BbpN2N3ΔLock, and BbpN2N3ΔLatch and detected 
with anti-BbpN2N3 and anti-rabbit-HRP.  The wells were developed and the absorbance was 
measured at 450 nm.  To assess the binding of the BbpCys-Cys, Fg-coated wells were 
incubated with the BbpN2N3 or BbpCys-Cys in the presence or absence of 5 mM dithiothreitol 
(DTT). 
 
BbpCys-Cys Far Western- Laemmli sample buffer containing 10 mM DTT was added to Fg 
for SDS-PAGE separation followed by transferring to nitrocellulose.  The membranes were 
blocked with 1% BSA and probed with BbpCys-Cys (15 µg/ml) in the presence or absence 
of 5 mM DTT in TBST, followed by detection with anti-BbpN2N3 and anti-rabbit-AP.   
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RESULTS 
 
BbpN2N3 mutants were designed by MSCRAMM comparison. 
To reveal the locking and latching sequences and closed disulfide bond locations in 
Bbp, two approaches were taken.  First, the amino acid sequences corresponding to the 
N2N3 domains of Bbp, SdrG and ClfA were aligned using Clustal (Figure 4-1).  Second, the 
structure of BbpN2N3 was modeled based on solved MSCRAMM structures using Ribbons 
(Figure 3-3).  The analyses revealed that the lock and latch truncations are at Ile583 and 
Ser589, respectively.  Furthermore, structural analysis predicted that the residues Glu376 and 
Pro598 are positioned in a way that if substituted to Cys, they can form a disulfide bond.  
Therefore, BbpN2N3 containing the substitutions E376C and P598C was constructed.   
 
The lock and latch are necessary for BbpN2N3 binding. 
 In order to assess whether the binding of BbpN2N3 to Fg is dependent upon the 
locking and latching residues, a solid-phase ELISA-type assay was conducted. Increasing 
concentrations of soluble BbpN2N3,, BbpN2N3ΔLock, and BbpN2N3ΔLatch (0.01 to 10.0 µM) 
were used to probe microtiter wells coated with Fg, followed by detection with polyclonal 
anti-BbpN2N3 and HRP conjugated anti-rabbit polyclonal.  In this assay, BbpN2N3 recognized 
Fg in a concentration-dependent, saturable manner but BbpN2N3ΔLock and BbpN2N3ΔLatch 
failed to bind to Fg (Figure 4-2b).  This indicates that the binding of Bbp to Fg requires the 
carboxy-terminal residues in the lock and latch sequences. 
 
An open conformation is required for BbpN2N3 binding to Fg. 
I determined whether an engineered disulfide bond could force the protein into a closed 
conformation.  SDS-PAGE in the absence or presence of reducing agent indicated that the 
reduced protein was larger in size.  This suggests that the reduction of disulfide  
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Figure 4-1.  Alignment of the N2N3 domains of SdrG, ClfA, and Bbp. Red - conserved motif; 
green – lock;  yellow – latch;  blue – cysteine mutations. 
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Figure 4-2.  Delta lock and latch BbpN2N3 mutants.  (A)  Coomassie stained SDS-
PAGE of BbpN2N3,, BbpN2N3ΔLock, and BbpN2N3ΔLatch.  (B)  Fg-coated wells were 
incubated with increasing concentrations of BbpN2N3,, BbpN2N3ΔLock, and 
BbpN2N3ΔLatch (0.01 to 10.0 µM)  followed by anti-BbpN2N3 and anti-rabbit-HRP. 
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bonds in the sample slows the migration, presumably due to the larger, open conformation 
of the protein (Figure 4-3a).   
 The binding to Fg by a double cysteine mutant that formed a disulfide bond between 
the N2 and N3 domains rendering the molecule in a closed form was examined.  Fg-coated 
wells were probed with increasing concentrations (15 – 1000 nM) of BbpN2N3 or BbpCys-
Cys.  Results indicate that the closed form of BbpN2N3 does not bind to Fg (Figure 4-3b).   
 In order to verify that the abrogation of binding was caused by the closing of the 
binding site, experiments were performed to rescue the binding of BbpCys-Cys. Far 
Western blotting was used to compare binding of reduced and nonreduced BbpCys-Cys 
(Figure 4-4a).  A Fg blot probed with BbpCys-Cys in the absence of DTT did not result in 
signal detection.  However, probing with BbpCys-Cys in the presence of DTT resulted in 
binding.  Furthermore, I performed a similar analysis using a solid-phase binding assay.  
Fg-coated wells were incubated with BbpN2N3 and BbpCysCys in the presence of 5 mM DTT 
(Figure 4-4b).  The results indicate that re-opening the closed form of Bbp by disulfide 
reduction restores the binding of BbpCys-Cys to similar levels as those of BbpN2N3.  
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Figure 4-3.  BbpCys-Cys.  (A)  BbpCys-Cys was separated on SDS-PAGE in 
nonreducing and reducing buffer.  (B).  Fg-coated wells were incubated with increasing 
concentrations (15 – 1000 nM) of BbpN2N3 or BbpCys-Cys followed by anti-BbpN2N3 
polyclonal antibody and anti-rabbit-HRP.  
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Figure 4-4.  Rescue of BbpCys-Cys binding.  (A)  Reduced Fg was separated on SDS-
PAGE and transferred to nitrocellulose membrane for Far Western analysis with  
BbpCys-Cys (15 µg/ml) in the presence (left) or absence (right) of 5 mM DTT followed by 
rabbit-anti BbpN2N3 polyclonal antibody and goat-anti-rabbit-AP.  (B)  Fg-coated wells 
were incubated with increasing concentrations of BbpN2N3 or BbpCys-Cys in the presence 
of 5 mM DTT followed by anti-BbpN2N3 and anti-rabbit-HRP. 
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DISCUSSION 
 
 The dock, lock, and latch, or variant thereof, has been proposed as the binding 
mechanism for MSCRAMMs.  In this study, BbpN2N3 mutants were constructed to examine 
the effects on binding imparted by the presence of the residues in the carboxy-terminus of 
the N3 domain known as the lock and latch residues.   
 In the S. epidermidis MSCRAMM SdrG, ligand binding induces conformational 
changes that include a redirection of the locking residues followed by β-strand 
complementation that morphs the protein into a closed form with the ligand inside of the 
binding trench.  Therefore, appropriate BbpN2N3 constructs were designed by the aid of 
computer modeling and sequence alignment.  These constructs were used to evaluate the 
regions required for Bbp to bind to Fg.  Results indicate that BbpN2N3 requires both the lock 
and latch for binding.  Additionally, a disulfide-bonded closed mutant did not bind to Fg, but 
the binding was restored by reduction of the disulfide bond, indicating that the protein must 
be open for Fg binding.  Therefore, the evidence strongly suggests that Bbp binds to Fg 
using the dock, lock, and latch model. 
 Further studies are required in order to prove our hypothesis.  To date, the structure 
of the ligand binding domains of Bbp either in apo-form or in a complex with the ligand have 
not been solved.  Once the structures of the different forms of Bbp are solved, the residues 
in the protein that bind to the target can be analyzed.  Structural assessment of the two 
forms of BbpN2N3 will support the evidence I have gathered biochemically. 
 Previous studies identified that Bbp inhibits fibrin binding.  Although no data has 
been gathered to examine this inhibition in more detail, the dynamic dock, lock, and latch 
mechanism could be playing a role.  The latching of the Fg molecule into the ligand-binding 
trench could render the αC domain unavailable for lateral aggregation of fibrils and could 
inhibit Factor XIIIa from covalently crosslinking the chains.  
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 The species tropism of Bbp poses some challenges in designing future experiments.  
The previous study indicated that Bbp was highly specific for the human Fg sequence.  
Therefore, it is possible that in order to progress to animal studies utilizing Bbp, partially 
humanized Aα mice will be required.  Until such a model is available, conducting 
biochemical, structural, and in vitro experiments will provide further understanding of the 
interaction between Bbp and Fg.  Moreover, the consequences of Bbp binding to fibrinogen 
can be studied. 
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CHAPTER V 
Discussion 
 
 Current staphylococcal therapy involves antibiotic use.  However, this is not a 
preventive approach to halt the spread of staphylococcal infections.  Preclinical and clinical 
vaccine studies have targeted bacterial surface and secreted factors.  A combination, or 
multivalent, vaccine that targets several factors could prove to be successful.  In the 
present studies, I sought to analyze two potential virulence factors. 
In the second chapter, the epidemiologically suggested link between the Panton-
Valentine Leukocidin (PVL) and necrotizing pneumonia was analyzed.  Using a murine 
model of pneumonia, the ability of a highly purified PVL toxin preparation to cause 
pneumonia (71) was discovered.  Furthermore, the ability of the toxin subunits to elicit a 
protective response was examined (13).  LukS-PV-vaccinated animals exhibited less 
morbidity and mortality when challenged with a lethal dose of the S. aureus strain USA300, 
which is a predominant antibiotic resistant clone causing CA-MRSA infections.  
While the results were able to attribute necrotizing pneumonia to the PVL toxin, the 
mechanism for this event has not been fully elucidated.  As previously discussed, PVL lyses 
monocytes, macrophages, and polymorphonuclear cells, and this interaction can lead to 
leukocyte release of inflammatory mediators.  Future experiments are needed to fully 
decipher the mechanisms by which PVL causes the severe inflammatory response 
observed in the lungs of mice instilled with purified protein. Specifically, whether the toxin 
itself can cause necrotizing pneumonia in leukocyte-deficient mice has not been determined 
because these mice experience high morbidity upon staphylococcal exposure.  A different 
approach to gather valuable information would be to use mutant PVL that cannot 
oligomerize or cause cell lysis.  This method was successful for the closely-related α-
Hemolysin.   
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  In the third and fourth chapters, data from experiments conducted with the cell-
surface adhesin, Bbp, are presented.  Bbp binds to bone-sialoprotein, indicating a role in 
osteomyelitis.  The ability of MSCRAMMs to bind to multiple ligands has been documented 
for several proteins, and this work identified a novel ligand for the MSCRAMM Bbp.  Also, 
experiments were performed to decipher the binding mechanism of Bbp to Fg. 
Screening a panel of typical MSCRAMM ligands for Bbp binding resulted in the 
identification of fibrinogen (Fg) as a target for Bbp (Figure 3-5).  The binding site was 
mapped to the αC region, residues 561-575, and peptide studies confirmed the results 
(Figures 3-11, 3-12, and 3-13).  Furthermore, Bbp exhibits high specificity and affinity for 
human Fg (Figures 3-6 and 3-7).  
I am beginning to examine the consequences of Bbp binding to Fg.  Already, I have 
accumulated data showing that Bbp inhibits fibrin formation (Figure 3-15).  However, the 
mechanism underlying this phenomenon has not been studied.  It is likely that binding of 
Bbp to the αC domain causes steric hindrance that inhibits the lateral aggregation of 
protofibrils to form fibrin.  Furthermore, the transglutaminase Factor XIIIa covalently links 
the α chain to itself and to γ chains.  The binding site, and surrounding residues, on αC 
contain amino acids that are believed to be involved in crosslinking of fibrin (116).  
Therefore, this is a possible mechanism of inhibition.  Studies conducted with αC mutants 
may aid in deciphering the mechanism by which Bbp inhibits fibrin formation. 
The binding site of Bbp on Fg contains an RGD motif.  This specific RGD has been 
shown to bind to integrins present on endothelial cells, platelets, and fibroblasts.  No 
experiments have been performed to examine the effects of Bbp on Fg-integrin binding.  
Presumably, binding of Bbp to αC would occupy the integrin-binding site, or, at the very 
least, the residues immediately amino-terminal to the integrin binding RGD.  Therefore, I 
 100 
expect that pretreatment of αC with Bbp would directly inhibit or sterically hinder the 
integrin-Fg interaction. 
The mechanism of Bbp binding to Fg was studied.  The data gathered indicate that 
this interaction occurs via the dock, lock, and latch (DLL) model.  Currently, our laboratory 
is working to obtain a co-crystal structure of Bbp with a Fg peptide.  A solved structure 
would provide the evidence necessary to identify the residues in Bbp that interact with the 
amino acids in human Fg.  These data could pave the way for the design of inhibitors to 
abrogate the interaction.  Because the Bbp binding site includes an RGD site, care must be 
taken not to inhibit important interactions between Fg and integrins necessary for normal 
biological functions. For example, our laboratory recently reported the identification of 
peptides that inhibit the interaction between ClfA and Fg but have no effect on the 
interaction between Fg and the platelet integrin (43).  
Evidence suggests that MSCRAMMs can serve as protective targets for a 
staphylococcal vaccine.  Therefore, our laboratory has worked to identify the molecular 
interactions between the surface adhesins and the human host.  Interestingly, Bbp has 
been previously termed as an allelic variant of SdrE.  I have begun to study SdrE in 
comparison to Bbp.  The two variants have been subjected to sequence alignment for 
comparison (Figure 5-1).  Interestingly, this analysis revealed that the N2N3 domains have 
the highest sequence variation (approximately 60% identity), but the N1, B repeats, and SD 
regions have identities above 90%.  Furthermore, a crystal structure of the SdrEN2N3 
domains has been solved (Unpublished data by Dr. Vannakambadi Ganesh).  A model of 
BbpN2N3 based on the SdrEN2N3 structure indicates that the structure of BbpN2N3 is more rigid 
in nature (Figure 5-2).  Specifically, the β-strands that compose the β-sandwiches are 
longer in BbpN2N3; whereas in SdrEN2N3, the β-sheets are shorter, requiring more inter-strand 
linker regions.   
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Figure 5-2.  Structural comparison of SdrE and Bbp.  The N2 domains are at the bottom 
and the N3 domains are at the top of the images.   
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The added flexibility of the SdrEN2N3 domains was predicted to correlate with activity.  
Preliminary experiments examining the differences in binding abilities and specificity were 
performed with the two variants.  First, the ability of SdrEN2N3 to bind to Fg was examined 
(Figure5-3a).  The results indicate that SdrEN2N3 binds to Fg in a concentration-dependent, 
saturable manner.  Furthermore, a species screen revealed that SdrEN2N3 exhibits a wider 
species tropism for Fg than BbpN2N3 (Figure 5-3b).  Human, feline, canine, bovine, ovine, 
rat, and porcine Fg all supported binding to SdrEN2N3, albeit at different levels.  Next, I 
determined if the increased flexibility and tropism of SdrE affected its activity towards 
human Fg.  A fibrin inhibition assay revealed that SdrEN2N3 was capable of inhibiting 
thrombin-catalyzed fibrin formation to similar levels as BbpN2N3 (Figure 5-3c).  However, a 
higher concentration of SdrEN2N3 is required to reach maximum inhibition.  These 
preliminary data indicate differences in the structure and activities of the ligand binding 
domains of SdrE and Bbp.  Future experiments to biochemically define the differences 
between the two proteins could be performed with the same reagents that were used to 
study the interaction between Bbp and Fg.  Although the data with SdrE and Fg are 
preliminary, I have identified the only known ligand of SdrE. 
The MSCRAMMs IsdA, IsdB, SdrD, and SdrE were identified as protective targets in 
an intravenous infection model (118).  Vaccination with SdrE led to high antibody titers and 
a reduction of bacteria in the kidneys.  Considering the data generated with SdrE and Bbp, 
it is possible that Bbp could also serve as a protective immunogen.  However, Bbp was not 
examined in that study.  It is also important to note that animal studies with Bbp may not be 
fully translational to human disease because it only targets human Fg.  Therefore, future 
experiments examining the in vivo role of Bbp may require the utilization of mice with 
partially humanized Fg.   
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Figure 5-3.  Comparison of SdrEN2N3 and BbpN2N3 activities. Human (A) or other species 
(B) Fg-coated wells were incubated with increasing concentrations (50-1000 nM) (A) or 
500 nM SdrEN2N3 and BbpN2N3 followed by protein-specific antibodies and goat-anti 
rabbit-HRP. (C) Human Fg coated wells were preincubated with 0.03-10 µM proteins 
prior to α-thrombin addition. 
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The studies encompassing this dissertation provide new functional data regarding 
putative staphylococcal virulence factors.  Studying putative virulence factors in animal 
models of disease can provide urgent information necessary for the understanding of 
complicated disease states.  Furthermore, identification of novel ligands for bacterial 
proteins can lead to the discovery of virulence mechanisms.  
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